US513030A
(en)
|
|
1894-01-16 |
|
Machine for waxing or coating paper |
DE133885C
(ko)
|
|
|
|
|
US2878264A
(en)
|
|
1959-03-17 |
|
Substituted amino alcohols |
CH372667A
(de)
|
1957-09-26 |
1963-10-31 |
Robins Co Inc A H |
Verfahren zur Herstellung von 3-Aryl-3-pyrrolidinolen
|
US3135766A
(en)
|
1961-10-03 |
1964-06-02 |
Mead Johnson & Co |
3-substituted-3-pyrrolidinols
|
US3484473A
(en)
|
1967-05-12 |
1969-12-16 |
Buckman Labor Inc |
Methylene bisesters of thiolsulfonic acids
|
DE1934150A1
(de)
|
1968-07-10 |
1970-01-15 |
Pennwalt Corp |
Neue 1-Alkanoyloxy-1,2,4,5-tetrahydro-3H,3-benzazepine
|
US3687808A
(en)
|
1969-08-14 |
1972-08-29 |
Univ Leland Stanford Junior |
Synthetic polynucleotides
|
US3745162A
(en)
|
1970-08-31 |
1973-07-10 |
Robins Co Inc A H |
1,2,3,4-tetrahydroisoquinoline-2-(thio)-carboxamides
|
GB1448437A
(en)
|
1973-02-24 |
1976-09-08 |
Beecham Group Ltd |
Diphenylpropylamines
|
US4022791A
(en)
|
1975-06-03 |
1977-05-10 |
Pfizer Inc. |
2-Aminomethyl-3,4-dihydronaphthalenes
|
GB1504424A
(en)
|
1975-08-09 |
1978-03-22 |
Beecham Group Ltd |
Isoquinoline-derived aminoethers
|
BR7807288A
(pt)
|
1977-11-08 |
1979-06-12 |
Genentech Inc |
Processo para sintese de polinucleotidos
|
DD133885B1
(de)
|
1978-01-04 |
1981-02-25 |
Hans Lehmann |
Mittel zur bekaempfung von phytopathogenen bakterien und pilzen
|
US4500707A
(en)
|
1980-02-29 |
1985-02-19 |
University Patents, Inc. |
Nucleosides useful in the preparation of polynucleotides
|
US4458066A
(en)
|
1980-02-29 |
1984-07-03 |
University Patents, Inc. |
Process for preparing polynucleotides
|
US5132418A
(en)
|
1980-02-29 |
1992-07-21 |
University Patents, Inc. |
Process for preparing polynucleotides
|
US4668777A
(en)
|
1981-03-27 |
1987-05-26 |
University Patents, Inc. |
Phosphoramidite nucleoside compounds
|
US4973679A
(en)
|
1981-03-27 |
1990-11-27 |
University Patents, Inc. |
Process for oligonucleo tide synthesis using phosphormidite intermediates
|
US4415732A
(en)
|
1981-03-27 |
1983-11-15 |
University Patents, Inc. |
Phosphoramidite compounds and processes
|
US4542142A
(en)
|
1982-11-22 |
1985-09-17 |
Roussel Uclaf |
Insecticidal cyclopropane carboxylic acid derivatives with 3-unsaturated-side chain
|
USRE34069E
(en)
|
1983-08-18 |
1992-09-15 |
Biosyntech Gmbh |
Process for the preparation of oligonucleotides
|
DE3329892A1
(de)
|
1983-08-18 |
1985-03-07 |
Köster, Hubert, Prof. Dr., 2000 Hamburg |
Verfahren zur herstellung von oligonucleotiden
|
US5118800A
(en)
|
1983-12-20 |
1992-06-02 |
California Institute Of Technology |
Oligonucleotides possessing a primary amino group in the terminal nucleotide
|
US5643889A
(en)
|
1984-07-11 |
1997-07-01 |
Temple University-Of The Commonwealth System Of Pennsylvania |
Cholesterol conjugates of 2'5'-oligoadenylate derivatives and antiviral uses thereof
|
FR2567892B1
(fr)
|
1984-07-19 |
1989-02-17 |
Centre Nat Rech Scient |
Nouveaux oligonucleotides, leur procede de preparation et leurs applications comme mediateurs dans le developpement des effets des interferons
|
US5367066A
(en)
|
1984-10-16 |
1994-11-22 |
Chiron Corporation |
Oligonucleotides with selectably cleavable and/or abasic sites
|
FR2575751B1
(fr)
|
1985-01-08 |
1987-04-03 |
Pasteur Institut |
Nouveaux nucleosides de derives de l'adenosine, leur preparation et leurs applications biologiques
|
FR2576898B1
(fr)
|
1985-02-01 |
1988-01-08 |
Lafon Labor |
Derives de 3-phenyl-tetrahydropyridine, procede de preparation et utilisation en therapeutique
|
US4659774A
(en)
|
1985-11-01 |
1987-04-21 |
American Hoechst Corporation |
Support for solid-phase oligonucleotide synthesis
|
US4840956A
(en)
|
1986-02-18 |
1989-06-20 |
Warner-Lambert Company |
Novel disubstituted-7-pyrrolidinoquinoline antibacterial agents
|
US4735949A
(en)
|
1986-02-18 |
1988-04-05 |
Warner-Lambert Company |
Disubstituted-7-pyrrolidinonaphthyridine antibacterial agents
|
IL83663A0
(en)
|
1986-10-27 |
1988-01-31 |
Robins Co Inc A H |
Preparation of 3-pyrrolidinols
|
WO1988010264A1
(en)
|
1987-06-24 |
1988-12-29 |
Howard Florey Institute Of Experimental Physiology |
Nucleoside derivatives
|
EP0302349B1
(en)
|
1987-07-30 |
1993-09-29 |
Bar Ilan University |
Biologically active carboxylic acid esters
|
US4923901A
(en)
|
1987-09-04 |
1990-05-08 |
Millipore Corporation |
Membranes with bound oligonucleotides and peptides
|
US5175273A
(en)
|
1988-07-01 |
1992-12-29 |
Genentech, Inc. |
Nucleic acid intercalating agents
|
US5047524A
(en)
|
1988-12-21 |
1991-09-10 |
Applied Biosystems, Inc. |
Automated system for polynucleotide synthesis and purification
|
US5262530A
(en)
|
1988-12-21 |
1993-11-16 |
Applied Biosystems, Inc. |
Automated system for polynucleotide synthesis and purification
|
JP2794461B2
(ja)
|
1989-08-17 |
1998-09-03 |
有機合成薬品工業株式会社 |
ホスホアミダイト化合物及びそれを用いたオリゴリボヌクレオチドの固相合成法
|
US5141813A
(en)
|
1989-08-28 |
1992-08-25 |
Clontech Laboratories, Inc. |
Multifunctional controlled pore glass reagent for solid phase oligonucleotide synthesis
|
US5134066A
(en)
|
1989-08-29 |
1992-07-28 |
Monsanto Company |
Improved probes using nucleosides containing 3-dezauracil analogs
|
CA2029273A1
(en)
|
1989-12-04 |
1991-06-05 |
Christine L. Brakel |
Modified nucleotide compounds
|
US5130302A
(en)
|
1989-12-20 |
1992-07-14 |
Boron Bilogicals, Inc. |
Boronated nucleoside, nucleotide and oligonucleotide compounds, compositions and methods for using same
|
CA2071897A1
(en)
|
1989-12-28 |
1991-06-29 |
Richard A. Glennon |
Sigma receptor ligands and the use thereof
|
US5212295A
(en)
|
1990-01-11 |
1993-05-18 |
Isis Pharmaceuticals |
Monomers for preparation of oligonucleotides having chiral phosphorus linkages
|
US5681941A
(en)
|
1990-01-11 |
1997-10-28 |
Isis Pharmaceuticals, Inc. |
Substituted purines and oligonucleotide cross-linking
|
US5506212A
(en)
|
1990-01-11 |
1996-04-09 |
Isis Pharmaceuticals, Inc. |
Oligonucleotides with substantially chirally pure phosphorothioate linkages
|
US5620963A
(en)
|
1991-10-15 |
1997-04-15 |
Isis Pharmaceuticals, Inc. |
Oligonucleotides for modulating protein kinase C having phosphorothioate linkages of high chiral purity
|
US5646265A
(en)
|
1990-01-11 |
1997-07-08 |
Isis Pharmceuticals, Inc. |
Process for the preparation of 2'-O-alkyl purine phosphoramidites
|
US5914396A
(en)
|
1990-01-11 |
1999-06-22 |
Isis Pharmaceuticals, Inc. |
2'-O-modified nucleosides and phosphoramidites
|
US6339066B1
(en)
|
1990-01-11 |
2002-01-15 |
Isis Pharmaceuticals, Inc. |
Antisense oligonucleotides which have phosphorothioate linkages of high chiral purity and which modulate βI, βII, γ, δ, Ε, ζ and η isoforms of human protein kinase C
|
US5459255A
(en)
|
1990-01-11 |
1995-10-17 |
Isis Pharmaceuticals, Inc. |
N-2 substituted purines
|
US5457191A
(en)
|
1990-01-11 |
1995-10-10 |
Isis Pharmaceuticals, Inc. |
3-deazapurines
|
US5635488A
(en)
|
1991-10-15 |
1997-06-03 |
Isis Pharmaceuticals, Inc. |
Compounds having phosphorodithioate linkages of high chiral purity
|
US5587470A
(en)
|
1990-01-11 |
1996-12-24 |
Isis Pharmaceuticals, Inc. |
3-deazapurines
|
WO1993013121A1
(en)
|
1991-12-24 |
1993-07-08 |
Isis Pharmaceuticals, Inc. |
Gapped 2' modified oligonucleotides
|
US5587361A
(en)
|
1991-10-15 |
1996-12-24 |
Isis Pharmaceuticals, Inc. |
Oligonucleotides having phosphorothioate linkages of high chiral purity
|
WO1991010671A1
(en)
|
1990-01-11 |
1991-07-25 |
Isis Pharmaceuticals, Inc. |
Compositions and methods for detecting and modulating rna activity and gene expression
|
US7101993B1
(en)
|
1990-01-11 |
2006-09-05 |
Isis Pharmaceuticals, Inc. |
Oligonucleotides containing 2′-O-modified purines
|
US5852188A
(en)
|
1990-01-11 |
1998-12-22 |
Isis Pharmaceuticals, Inc. |
Oligonucleotides having chiral phosphorus linkages
|
US5292875A
(en)
|
1990-04-20 |
1994-03-08 |
Lynx Therapeutics, Inc. |
Method of synthesizing sulfurized oligonucleotide analogs
|
US5151510A
(en)
|
1990-04-20 |
1992-09-29 |
Applied Biosystems, Inc. |
Method of synethesizing sulfurized oligonucleotide analogs
|
ES2139578T3
(es)
|
1990-05-23 |
2000-02-16 |
Isis Pharmaceuticals Inc |
Composiciones y procedimiento para modular la actividad del arn mediante la modificacion de la estructura protectora 5' del arn.
|
US5869641A
(en)
|
1990-06-11 |
1999-02-09 |
Nexstar Pharmaceuticals, Inc. |
High affinity nucleic acid ligands of CD4
|
US5503978A
(en)
|
1990-06-11 |
1996-04-02 |
University Research Corporation |
Method for identification of high affinity DNA ligands of HIV-1 reverse transcriptase
|
US5580737A
(en)
|
1990-06-11 |
1996-12-03 |
Nexstar Pharmaceuticals, Inc. |
High-affinity nucleic acid ligands that discriminate between theophylline and caffeine
|
US6331394B1
(en)
|
1991-06-10 |
2001-12-18 |
Gilead Sciences, Inc. |
Nucleic acid ligands to integrins
|
US5705337A
(en)
|
1990-06-11 |
1998-01-06 |
Nexstar Pharmaceuticals, Inc. |
Systematic evolution of ligands by exponential enrichment: chemi-SELEX
|
US5567588A
(en)
|
1990-06-11 |
1996-10-22 |
University Research Corporation |
Systematic evolution of ligands by exponential enrichment: Solution SELEX
|
US5726017A
(en)
|
1990-06-11 |
1998-03-10 |
Nexstar Pharmaceuticals, Inc. |
High affinity HIV-1 gag nucleic acid ligands
|
US5527894A
(en)
|
1990-06-11 |
1996-06-18 |
Nexstar Pharmacueticals, Inc. |
Ligands of HIV-1 tat protein
|
US5654151A
(en)
|
1990-06-11 |
1997-08-05 |
Nexstar Pharmaceuticals, Inc. |
High affinity HIV Nucleocapsid nucleic acid ligands
|
US5496938A
(en)
|
1990-06-11 |
1996-03-05 |
Nexstar Pharmaceuticals, Inc. |
Nucleic acid ligands to HIV-RT and HIV-1 rev
|
US6001577A
(en)
|
1998-06-08 |
1999-12-14 |
Nexstar Pharmaceuticals, Inc. |
Systematic evolution of ligands by exponential enrichment: photoselection of nucleic acid ligands and solution selex
|
US5780228A
(en)
|
1990-06-11 |
1998-07-14 |
Nexstar Pharmaceuticals, Inc. |
High affinity nucleic acid ligands to lectins
|
ES2110444T3
(es)
|
1990-06-11 |
1998-02-16 |
Nexstar Pharmaceuticals Inc |
Ligandos de acidos nucleicos.
|
US5587468A
(en)
|
1990-06-11 |
1996-12-24 |
University Research Corporation |
High affinity nucleic acid ligands to HIV integrase
|
US5846713A
(en)
|
1990-06-11 |
1998-12-08 |
Nexstar Pharmaceuticals, Inc. |
High affinity HKGF nucleic acid ligands and inhibitors
|
US6261774B1
(en)
|
1990-06-11 |
2001-07-17 |
Gilead Sciences, Inc. |
Truncation selex method
|
US5668264A
(en)
|
1990-06-11 |
1997-09-16 |
Nexstar Pharmaceuticals, Inc. |
High affinity PDGF nucleic acid ligands
|
US5543293A
(en)
|
1990-06-11 |
1996-08-06 |
Nexstar Pharmaceuticals, Inc. |
DNA ligands of thrombin
|
US6232071B1
(en)
|
1990-06-11 |
2001-05-15 |
Gilead Sciences, Inc. |
Tenascin-C nucleic acid ligands
|
US5683867A
(en)
|
1990-06-11 |
1997-11-04 |
Nexstar Pharmaceuticals, Inc. |
Systematic evolution of ligands by exponential enrichment: blended SELEX
|
US5637459A
(en)
|
1990-06-11 |
1997-06-10 |
Nexstar Pharmaceuticals, Inc. |
Systematic evolution of ligands by exponential enrichment: chimeric selex
|
US5861254A
(en)
|
1997-01-31 |
1999-01-19 |
Nexstar Pharmaceuticals, Inc. |
Flow cell SELEX
|
WO1992002258A1
(en)
|
1990-07-27 |
1992-02-20 |
Isis Pharmaceuticals, Inc. |
Nuclease resistant, pyrimidine modified oligonucleotides that detect and modulate gene expression
|
US5610289A
(en)
|
1990-07-27 |
1997-03-11 |
Isis Pharmaceuticals, Inc. |
Backbone modified oligonucleotide analogues
|
US5432272A
(en)
|
1990-10-09 |
1995-07-11 |
Benner; Steven A. |
Method for incorporating into a DNA or RNA oligonucleotide using nucleotides bearing heterocyclic bases
|
US5512668A
(en)
|
1991-03-06 |
1996-04-30 |
Polish Academy Of Sciences |
Solid phase oligonucleotide synthesis using phospholane intermediates
|
US7015315B1
(en)
|
1991-12-24 |
2006-03-21 |
Isis Pharmaceuticals, Inc. |
Gapped oligonucleotides
|
US6414112B1
(en)
|
1991-05-24 |
2002-07-02 |
Ole Buchardt |
Peptide nucleic acids having 2,6-diaminopurine nucleobases
|
JPH04348077A
(ja)
|
1991-05-24 |
1992-12-03 |
Nec Corp |
薄膜トランジスタ
|
TW360711B
(en)
|
1991-06-10 |
1999-06-11 |
Lucky Ltd |
CDNAs of Korean hepatitis C virus and polypeptides encoded thereby
|
US5359052A
(en)
|
1991-08-05 |
1994-10-25 |
Polish Academy Of Sciences |
Chalcophospholanes useful in the synthesis of oligonucleoside phosphorothioates, phosphorodithioates and related selenates
|
US5646267A
(en)
|
1991-08-05 |
1997-07-08 |
Polish Academy Of Sciences |
Method of making oligonucleotides and oligonucleotide analogs using phospholanes and enantiomerically resolved phospholane analogues
|
US7119184B2
(en)
|
1991-08-12 |
2006-10-10 |
Isis Pharmaceuticals, Inc. |
Oligonucleotides having A-DNA form and B-DNA form conformational geometry
|
US6369209B1
(en)
|
1999-05-03 |
2002-04-09 |
Isis Pharmaceuticals, Inc. |
Oligonucleotides having A-DNA form and B-DNA form conformational geometry
|
CA2121144C
(en)
|
1991-10-15 |
2001-07-31 |
Phillip Dan Cook |
Oligonucleotides having chiral phosphorus linkages
|
US5654284A
(en)
|
1991-10-15 |
1997-08-05 |
Isis Pharmaceuticals, Inc. |
Oligonucleotides for modulating RAF kinase having phosphorothioate linkages of high chiral purity
|
US5607923A
(en)
|
1991-10-15 |
1997-03-04 |
Isis Pharmaceuticals, Inc. |
Oligonucleotides for modulating cytomegalovirus having phosphorothioate linkages of high chiral purity
|
US5576302A
(en)
|
1991-10-15 |
1996-11-19 |
Isis Pharmaceuticals, Inc. |
Oligonucleotides for modulating hepatitis C virus having phosphorothioate linkages of high chiral purity
|
US5599797A
(en)
|
1991-10-15 |
1997-02-04 |
Isis Pharmaceuticals, Inc. |
Oligonucleotides having phosphorothioate linkages of high chiral purity
|
US5661134A
(en)
|
1991-10-15 |
1997-08-26 |
Isis Pharmaceuticals, Inc. |
Oligonucleotides for modulating Ha-ras or Ki-ras having phosphorothioate linkages of high chiral purity
|
DE59208572D1
(de)
|
1991-10-17 |
1997-07-10 |
Ciba Geigy Ag |
Bicyclische Nukleoside, Oligonukleotide, Verfahren zu deren Herstellung und Zwischenprodukte
|
US5594121A
(en)
|
1991-11-07 |
1997-01-14 |
Gilead Sciences, Inc. |
Enhanced triple-helix and double-helix formation with oligomers containing modified purines
|
US6235887B1
(en)
|
1991-11-26 |
2001-05-22 |
Isis Pharmaceuticals, Inc. |
Enhanced triple-helix and double-helix formation directed by oligonucleotides containing modified pyrimidines
|
US5484908A
(en)
|
1991-11-26 |
1996-01-16 |
Gilead Sciences, Inc. |
Oligonucleotides containing 5-propynyl pyrimidines
|
US5359044A
(en)
|
1991-12-13 |
1994-10-25 |
Isis Pharmaceuticals |
Cyclobutyl oligonucleotide surrogates
|
JPH08500481A
(ja)
|
1992-05-11 |
1996-01-23 |
リボザイム・ファーマシューティカルズ・インコーポレーテッド |
ウイルスの複製を阻害するための方法および薬剤
|
GB9213601D0
(en)
|
1992-06-26 |
1992-08-12 |
Mastico Robert A |
Protein based delivery system
|
CA2140343A1
(en)
|
1992-07-17 |
1994-02-03 |
Sean M. Sullivan |
Method and reagent for treatment of animal diseases
|
US7067497B2
(en)
|
1992-09-29 |
2006-06-27 |
Isis Pharmaceuticals, Inc. |
Modulation of telomere length by oligonucleotides having a G-core sequence
|
JPH08508714A
(ja)
|
1993-01-25 |
1996-09-17 |
ハイブライドン インコーポレイテッド |
オリゴヌクレオチド・アルキルホスホネートおよびアルキルホスホノチオエート
|
HU9501994D0
(en)
|
1993-03-31 |
1995-09-28 |
Sterling Winthrop Inc |
Novel 5'-substituted nucleosides and oligomers produced therefrom
|
US5955591A
(en)
|
1993-05-12 |
1999-09-21 |
Imbach; Jean-Louis |
Phosphotriester oligonucleotides, amidites and method of preparation
|
US6015886A
(en)
|
1993-05-24 |
2000-01-18 |
Chemgenes Corporation |
Oligonucleotide phosphate esters
|
EP0628394B1
(en)
|
1993-06-10 |
1998-08-26 |
Idemitsu Petrochemical Co. Ltd. |
Injection molding die
|
US5502177A
(en)
|
1993-09-17 |
1996-03-26 |
Gilead Sciences, Inc. |
Pyrimidine derivatives for labeled binding partners
|
US5643989A
(en)
|
1993-10-29 |
1997-07-01 |
Azdel, Inc. |
Fiber reinforced functionalized polyolefin composites
|
ES2307293T3
(es)
|
1993-10-29 |
2008-11-16 |
The Brigham And Women's Hospital, Inc. |
Utilizacion terapeutica de señuelos de elementos en cis in vivo.
|
US5457187A
(en)
|
1993-12-08 |
1995-10-10 |
Board Of Regents University Of Nebraska |
Oligonucleotides containing 5-fluorouracil
|
DE4435728A1
(de)
|
1994-01-19 |
1995-07-20 |
Boehringer Mannheim Gmbh |
Biotinsilan-Verbindungen und diese Verbindungen enthaltende Bindematrix
|
WO1995021853A1
(en)
|
1994-02-10 |
1995-08-17 |
Nexstar Pharmaceuticals, Inc. |
High-affinity ligands of basic fibroblast growth factor and thrombin
|
US6117679A
(en)
|
1994-02-17 |
2000-09-12 |
Maxygen, Inc. |
Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
|
AU1806795A
(en)
|
1994-02-22 |
1995-09-04 |
Novo Nordisk A/S |
A method of preparing a variant of a lipolytic enzyme
|
US5596091A
(en)
|
1994-03-18 |
1997-01-21 |
The Regents Of The University Of California |
Antisense oligonucleotides comprising 5-aminoalkyl pyrimidine nucleotides
|
RU2215034C2
(ru)
|
1994-05-11 |
2003-10-27 |
Новосимс А/С |
ФЕРМЕНТ С АКТИВНОСТЬЮ ЭНДО-1,3(4)-β-ГЛЮКАНАЗЫ, КОДИРУЮЩАЯ ЕГО ДНК И СПОСОБ ЕГО ПОЛУЧЕНИЯ
|
US5525711A
(en)
|
1994-05-18 |
1996-06-11 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Pteridine nucleotide analogs as fluorescent DNA probes
|
EP1167379A3
(en)
|
1994-07-15 |
2004-09-08 |
University Of Iowa Research Foundation |
Immunomodulatory oligonucleotides
|
US6239116B1
(en)
|
1994-07-15 |
2001-05-29 |
University Of Iowa Research Foundation |
Immunostimulatory nucleic acid molecules
|
US6207646B1
(en)
|
1994-07-15 |
2001-03-27 |
University Of Iowa Research Foundation |
Immunostimulatory nucleic acid molecules
|
EP0779893B1
(en)
|
1994-09-07 |
2001-06-27 |
Hybridon, Inc. |
Oligonucleotide prodrugs
|
US5681940A
(en)
|
1994-11-02 |
1997-10-28 |
Icn Pharmaceuticals |
Sugar modified nucleosides and oligonucleotides
|
WO1996019572A1
(en)
|
1994-12-22 |
1996-06-27 |
Hybridon, Inc. |
Synthesis of stereospecific oligonucleotide phosphorothioates
|
GB9501465D0
(en)
|
1995-01-25 |
1995-03-15 |
King S College London |
Nucleoside phosphorothioate derivatives,synthesis and use thereof
|
JPH10512894A
(ja)
|
1995-03-06 |
1998-12-08 |
アイシス・ファーマシューティカルス・インコーポレーテッド |
2’−o−置換ピリミジンおよびそのオリゴマー化合物の合成の改良法
|
AU5301996A
(en)
|
1995-03-06 |
1996-09-23 |
Nexstar Pharmaceuticals, Inc. |
High-affinity oligonucleotide ligands to secretory phospholipase a2(spla2)
|
US6166197A
(en)
|
1995-03-06 |
2000-12-26 |
Isis Pharmaceuticals, Inc. |
Oligomeric compounds having pyrimidine nucleotide (S) with 2'and 5 substitutions
|
EP0739983B1
(en)
|
1995-04-27 |
2009-12-30 |
Takara Bio Inc. |
Gene encoding lacto-n-biosidase
|
RU2205874C2
(ru)
|
1995-05-11 |
2003-06-10 |
Апплайд Резеч Системз Арс Холдинг Н.В. |
Нуклеотидная последовательность, способная ингибировать активность il-6, плазмидный вектор для трансфекции в клетки млекопитающих, нуклеотидная последовательность, используемая при терапии, фармацевтическая композиция (варианты)
|
AU5871196A
(en)
|
1995-05-23 |
1996-12-24 |
Hybridon, Inc. |
Methods and compounds for the synthesis of oligonucleotides and the oligonucleotides thereby produced
|
AU5869696A
(en)
|
1995-05-23 |
1996-12-11 |
Hybridon, Inc. |
Novel synthons for stereoselective oligonucleotide synthesis
|
JPH10510433A
(ja)
|
1995-06-06 |
1998-10-13 |
アイシス・ファーマシューティカルス・インコーポレーテッド |
高いキラル純度のホスホロチオエート結合を有するオリゴヌクレオチド
|
US6111095A
(en)
|
1995-06-07 |
2000-08-29 |
Merck & Co., Inc. |
Capped synthetic RNA, analogs, and aptamers
|
US5932450A
(en)
|
1995-06-07 |
1999-08-03 |
Gen-Probe Incorporated |
Enzymatic synthesis of oligonucleotides using digestible templates
|
US6699843B2
(en)
|
1995-06-07 |
2004-03-02 |
Gilead Sciences, Inc. |
Method for treatment of tumors using nucleic acid ligands to PDGF
|
EP0751222B1
(en)
|
1995-06-29 |
2006-03-01 |
Takara Bio Inc. |
Gene encoding endoglycoceramidase
|
EP0759470B1
(en)
|
1995-06-29 |
2006-10-25 |
Takara Bio Inc. |
Gene encoding endoglycoceramidase activator
|
US6017700A
(en)
*
|
1995-08-04 |
2000-01-25 |
Bayer Corporation |
Cationic oligonucleotides, and related methods of synthesis and use
|
US5936080A
(en)
|
1996-05-24 |
1999-08-10 |
Genta Incorporated |
Compositions and methods for the synthesis of organophosphorus derivatives
|
WO1997009443A1
(en)
|
1995-09-05 |
1997-03-13 |
Michigan State University |
PROCESS FOR THE ISOLATION AND PURIFICATION OF TAXOL AND TAXANES FROM TAXUS spp
|
US6476216B1
(en)
|
1995-10-20 |
2002-11-05 |
Mcgill University |
Preparation of phosphorothioate oligomers
|
US6160109A
(en)
|
1995-10-20 |
2000-12-12 |
Isis Pharmaceuticals, Inc. |
Preparation of phosphorothioate and boranophosphate oligomers
|
US5734041A
(en)
|
1995-10-20 |
1998-03-31 |
Mcgill University |
Preparation of chiral phosphorothioate oligomers
|
US5856085A
(en)
|
1995-12-01 |
1999-01-05 |
The Penn State Research Foundation |
Compositions and methods of developing oligonucleotides and oligonucleotide analogs having antiviral activity
|
US7018793B1
(en)
|
1995-12-07 |
2006-03-28 |
Diversa Corporation |
Combinatorial screening of mixed populations of organisms
|
DE69739880D1
(de)
|
1996-02-01 |
2010-07-01 |
Gilead Sciences Inc |
NUKLEINSÄURELIGANDEN MIT HOHER AFFINITÄT FÜR DAS C1q PROTEIN DES KOMPLEMENTSYSTEMS
|
US5998602A
(en)
|
1996-02-15 |
1999-12-07 |
The Cleveland Clinic Fouindation And Government |
RNase L activators and antisense oligonucleotides effective to treat RSV infections
|
US6214805B1
(en)
|
1996-02-15 |
2001-04-10 |
The United States Of America As Represented By The Department Of Health And Human Services |
RNase L activators and antisense oligonucleotides effective to treat RSV infections
|
GB9604669D0
(en)
|
1996-03-05 |
1996-05-01 |
Ciba Geigy Ag |
Chemical compounds
|
US5824669A
(en)
|
1996-03-22 |
1998-10-20 |
Nitromed, Inc. |
Nitrosated and nitrosylated compounds and compositions and their use for treating respiratory disorders
|
AU3025597A
(en)
|
1996-05-10 |
1997-12-05 |
Novo Nordisk A/S |
Method of providing novel dna sequences
|
US5856465A
(en)
|
1996-05-24 |
1999-01-05 |
Polska Akademia Nauk Centrum Badan Molekularnych I Makromolekularnych |
Compositions and methods for the synthesis of chirally pure organophosphorus nucleoside derivatives
|
US5898031A
(en)
|
1996-06-06 |
1999-04-27 |
Isis Pharmaceuticals, Inc. |
Oligoribonucleotides for cleaving RNA
|
DE19622783A1
(de)
|
1996-06-07 |
1997-12-11 |
Hoechst Ag |
Isolierung der Biosynthesegene für Pseudo-Oligosaccharide aus Streptomyces glaucescens GLA.O und ihre Verwendung
|
DE69736667T2
(de)
|
1996-07-16 |
2007-09-06 |
Gen-Probe Inc., San Diego |
Verfahren zum nachweis und amplifikation von nukleinsäuresequenzen unter verbrauch von modifizierten oligonukleotiden mit erhöhter zielschmelztemperatur (tm)
|
ATE311402T1
(de)
|
1996-07-24 |
2005-12-15 |
Buchardt Dorte |
Peptidnukleinsäuren mit erhöhter bindungsaffinität, sequenzspezifität und löslichkeit
|
AU4156197A
(en)
|
1996-08-21 |
1998-03-06 |
Hybridon, Inc. |
Oligonucleotide prodrugs
|
AU4161997A
(en)
|
1996-08-30 |
1998-03-19 |
Hybridon, Inc. |
Novel sulfur transfer reagents for oligonucleotide synthesis
|
US6056973A
(en)
|
1996-10-11 |
2000-05-02 |
Sequus Pharmaceuticals, Inc. |
Therapeutic liposome composition and method of preparation
|
US6051698A
(en)
|
1997-06-06 |
2000-04-18 |
Janjic; Nebojsa |
Vascular endothelial growth factor (VEGF) nucleic acid ligand complexes
|
EP0968226A4
(en)
|
1996-12-27 |
2001-02-14 |
Icn Pharmaceuticals |
OLIGOAPTAMERS WITH G-ENRICHED REGIONS AND METHODS FOR MODULATING AN IMMUNE RESPONSE
|
US6172209B1
(en)
|
1997-02-14 |
2001-01-09 |
Isis Pharmaceuticals Inc. |
Aminooxy-modified oligonucleotides and methods for making same
|
US6639062B2
(en)
|
1997-02-14 |
2003-10-28 |
Isis Pharmaceuticals, Inc. |
Aminooxy-modified nucleosidic compounds and oligomeric compounds prepared therefrom
|
US6369237B1
(en)
|
1997-03-07 |
2002-04-09 |
President And Fellows Of Harvard College |
DNA glycosylase inhibitors, and uses related thereto
|
US6015887A
(en)
|
1997-04-11 |
2000-01-18 |
Isis Pharmaceuticals, Inc. |
Chiral peptide nucleic acids and methods for preparing same
|
US6468983B2
(en)
|
1997-04-21 |
2002-10-22 |
The Cleveland Clinic Foundation |
RNase L activators and antisense oligonucleotides effective to treat telomerase-expressing malignancies
|
PL184612B1
(pl)
|
1997-04-25 |
2002-11-29 |
Pan |
Sposób wytwarzania modyfikowanych P chiralnych analogów nukleotydów
|
AU745309B2
(en)
|
1997-05-28 |
2002-03-21 |
Peter E. Nielsen |
Conjugated peptide nucleic acids having enhanced cellular uptake
|
US6589940B1
(en)
|
1997-06-06 |
2003-07-08 |
Dynavax Technologies Corporation |
Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof
|
WO1999005160A2
(en)
|
1997-07-25 |
1999-02-04 |
Hybridon, Inc. |
Oligonuclotides having 3' terminal stereospecific phosphorothioates
|
US6383808B1
(en)
|
2000-09-11 |
2002-05-07 |
Isis Pharmaceuticals, Inc. |
Antisense inhibition of clusterin expression
|
GB9717158D0
(en)
|
1997-08-13 |
1997-10-22 |
King S College London |
Solution synthesis of oligonucleotides and their phosphorothioate analogues
|
US6767739B2
(en)
|
2001-07-30 |
2004-07-27 |
Isis Pharmaceuticals Inc. |
Antisense modulation of microsomal triglyceride transfer protein expression
|
US6750344B1
(en)
|
1997-09-05 |
2004-06-15 |
Isis Pharmaceuticals, Inc. |
Amine compounds and combinatorial libraries comprising same
|
DE19741715A1
(de)
|
1997-09-22 |
1999-03-25 |
Hoechst Ag |
Pentopyranosyl-Nucleosid, seine Herstellung und Verwendung
|
US6617438B1
(en)
|
1997-11-05 |
2003-09-09 |
Sirna Therapeutics, Inc. |
Oligoribonucleotides with enzymatic activity
|
US6528640B1
(en)
|
1997-11-05 |
2003-03-04 |
Ribozyme Pharmaceuticals, Incorporated |
Synthetic ribonucleic acids with RNAse activity
|
US6080543A
(en)
|
1997-12-08 |
2000-06-27 |
E. & J. Gallo Winery |
Detection of fungal pathogens
|
US6582936B1
(en)
|
1997-12-12 |
2003-06-24 |
The Regents Of The University Of California |
Methods for making nucleic acids
|
US6248519B1
(en)
|
1998-03-11 |
2001-06-19 |
E & J Gallo Winery |
Detection of fermentation-related microorganisms
|
US7045610B2
(en)
|
1998-04-03 |
2006-05-16 |
Epoch Biosciences, Inc. |
Modified oligonucleotides for mismatch discrimination
|
JP2002513763A
(ja)
|
1998-05-06 |
2002-05-14 |
ユニバーシティ オブ アイオワ リサーチ ファウンデーション |
Cpgオリゴヌクレオチドを使用して寄生生物感染および関連する疾患を予防および処置するための方法
|
DE69927495T2
(de)
|
1998-05-14 |
2006-07-06 |
Coley Pharmaceutical Group, Inc., Wellesley |
Verfahren zur regulieren der hämatopoese mit hilfe von cpg-oligonukleotiden
|
US6242589B1
(en)
|
1998-07-14 |
2001-06-05 |
Isis Pharmaceuticals, Inc. |
Phosphorothioate oligonucleotides having modified internucleoside linkages
|
US6867294B1
(en)
*
|
1998-07-14 |
2005-03-15 |
Isis Pharmaceuticals, Inc. |
Gapped oligomers having site specific chiral phosphorothioate internucleoside linkages
|
JP2002521489A
(ja)
|
1998-07-27 |
2002-07-16 |
ユニバーシティ オブ アイオワ リサーチ ファウンデーション |
CpGオリゴヌクレオチドの立体異性体および関連する方法
|
DE69929444T2
(de)
|
1998-08-10 |
2006-09-28 |
Antigenics Inc., Woburn |
Cpg-zusammensetzungen, saponin-adjuvantien und verfahren zu deren verwendung
|
US6995249B1
(en)
|
1998-08-14 |
2006-02-07 |
Japan Science And Technology Corporation |
Nucleic acid capable of binding specifically to Ras target protein
|
WO2000023444A1
(en)
|
1998-10-21 |
2000-04-27 |
Abbott Laboratories |
5,7-disubstituted-4-aminopyrido[2,3-d]pyrimidine compounds
|
US6995259B1
(en)
|
1998-10-23 |
2006-02-07 |
Sirna Therapeutics, Inc. |
Method for the chemical synthesis of oligonucleotides
|
US6867289B1
(en)
|
1998-10-26 |
2005-03-15 |
Board Of Regents, The University Of Texas Systems |
Thio-modified aptamer synthetic methods and compositions
|
US6451524B1
(en)
|
1998-11-25 |
2002-09-17 |
Isis Pharmaceuticals, Inc. |
Identification of disease predictive nucleic acids
|
AU1742600A
(en)
|
1998-11-25 |
2000-06-13 |
Isis Pharmaceuticals, Inc. |
Identification of disease predictive nucleic acids
|
EP1141335B1
(en)
|
1998-12-21 |
2009-08-05 |
Genencor International, Inc. |
Chemically modified enzymes with multiple charged variants
|
CA2702148C
(en)
|
1999-01-06 |
2014-03-04 |
Genenews Inc. |
Method of profiling gene expression in a human subject having an infectious disease
|
US6265172B1
(en)
|
1999-02-08 |
2001-07-24 |
University Of Kentucky |
Diagnostic test and therapy for manganese superoxide dismutate (mNsod) associated diseases
|
US6121437A
(en)
|
1999-03-16 |
2000-09-19 |
Isis Pharmaceuticals, Inc. |
Phosphate and thiophosphate protecting groups
|
US6506594B1
(en)
|
1999-03-19 |
2003-01-14 |
Cornell Res Foundation Inc |
Detection of nucleic acid sequence differences using the ligase detection reaction with addressable arrays
|
GB9907245D0
(en)
|
1999-03-29 |
1999-05-26 |
Goldsborough Andrew |
Cleavage of nucleic acids from solid supports
|
JP3072345B1
(ja)
|
1999-03-31 |
2000-07-31 |
農林水産省家畜衛生試験場長 |
豚丹毒菌の組換えサブユニットワクチン
|
DE19916417A1
(de)
|
1999-04-01 |
2000-10-19 |
Schering Ag |
Amyloidspezifisches Aptamer
|
AU775412B2
(en)
|
1999-04-08 |
2004-07-29 |
Advanced Cancer Therapeutics, Inc. |
Antiproliferative activity of G-rich oligonucleotides and method of using same to bind to nucleolin
|
US6977245B2
(en)
|
1999-04-12 |
2005-12-20 |
The United States Of America As Represented By The Department Of Health And Human Services |
Oligodeoxynucleotide and its use to induce an immune response
|
US6300069B1
(en)
|
1999-05-03 |
2001-10-09 |
Qiagen Gmbh |
Generation and amplification of nucleic acids from ribonucleic acids
|
US6656730B1
(en)
|
1999-06-15 |
2003-12-02 |
Isis Pharmaceuticals, Inc. |
Oligonucleotides conjugated to protein-binding drugs
|
US6066500A
(en)
|
1999-06-25 |
2000-05-23 |
Isis Pharmaceuticals Inc. |
Antisense modulation of Beta catenin expression
|
US6271004B1
(en)
|
1999-06-25 |
2001-08-07 |
Display Systems Biotech A/S |
Method for improved reverse transcription at high temperatures
|
US6569630B1
(en)
|
1999-07-02 |
2003-05-27 |
Conceptual Mindworks, Inc. |
Methods and compositions for aptamers against anthrax
|
US6414135B1
(en)
|
1999-07-07 |
2002-07-02 |
Isis Pharmaceuticals, Inc. |
C3′-methylene hydrogen phosphonate monomers and related compounds
|
US20030092647A1
(en)
|
2001-08-08 |
2003-05-15 |
Crooke Rosanne M. |
Antisense modulation of cholesteryl ester transfer protein expression
|
DE19935756A1
(de)
|
1999-07-27 |
2001-02-08 |
Mologen Forschungs Entwicklung |
Kovalent geschlossenes Nukleinsäuremolekül zur Immunstimulation
|
US6171795B1
(en)
|
1999-07-29 |
2001-01-09 |
Nexstar Pharmaceuticals, Inc. |
Nucleic acid ligands to CD40ligand
|
US6147200A
(en)
|
1999-08-19 |
2000-11-14 |
Isis Pharmaceuticals, Inc. |
2'-O-acetamido modified monomers and oligomers
|
US7264932B2
(en)
|
1999-09-24 |
2007-09-04 |
Applera Corporation |
Nuclease inhibitor cocktail
|
DE60022665T2
(de)
|
1999-09-25 |
2006-06-22 |
Coley Pharmaceutical Gmbh |
Immunstimulierende nukeinsäuren
|
US6949520B1
(en)
|
1999-09-27 |
2005-09-27 |
Coley Pharmaceutical Group, Inc. |
Methods related to immunostimulatory nucleic acid-induced interferon
|
JP2003510290A
(ja)
|
1999-09-27 |
2003-03-18 |
コーリー ファーマシューティカル グループ,インコーポレイテッド |
免疫刺激核酸誘導インターフェロンに関する方法
|
US20020082227A1
(en)
|
1999-09-30 |
2002-06-27 |
Scott Henry |
Use of oligonucleotides for inhibition of complement activation
|
WO2001025488A2
(en)
|
1999-10-06 |
2001-04-12 |
Quark Biotech, Inc. |
Method for enrichment of natural antisense messenger rna
|
JP3463098B2
(ja)
|
1999-10-08 |
2003-11-05 |
独立行政法人産業技術総合研究所 |
モジュレートアプタマー及びこれを用いた標的タンパク質の検出方法
|
GB9924285D0
(en)
|
1999-10-14 |
1999-12-15 |
Avecia Ltd |
Process
|
US20010055761A1
(en)
|
1999-10-29 |
2001-12-27 |
Agilent Technologies |
Small scale dna synthesis using polymeric solid support with functionalized regions
|
FR2800750B1
(fr)
|
1999-11-05 |
2003-01-31 |
Centre Nat Rech Scient |
Proteines membranaires ctl (choline transporter like) impliquees dans le transport de la choline
|
WO2001040515A1
(en)
|
1999-11-12 |
2001-06-07 |
Isis Pharmaceuticals, Inc. |
Gapped oligomers having site specific chiral phosphorothioate internucleoside linkages
|
US6322985B1
(en)
|
1999-12-27 |
2001-11-27 |
Technion Research And Development Foundation Ltd. |
Abundant, well distributed and hyperpolymorphic simple sequence repeats in prokaryote genomes and use of same for prokaryote classification and typing
|
WO2001050349A1
(en)
|
1999-12-30 |
2001-07-12 |
Rutgers, The State University Of New Jersey |
Electronic document customization and transformation utilizing user feedback
|
JP2004510953A
(ja)
|
1999-12-30 |
2004-04-08 |
キャボット コーポレイション |
改良された性質を有するセンサー
|
US6649750B1
(en)
|
2000-01-05 |
2003-11-18 |
Isis Pharmaceuticals, Inc. |
Process for the preparation of oligonucleotide compounds
|
US6159697A
(en)
|
2000-01-19 |
2000-12-12 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of Smad7 expression
|
US7585847B2
(en)
|
2000-02-03 |
2009-09-08 |
Coley Pharmaceutical Group, Inc. |
Immunostimulatory nucleic acids for the treatment of asthma and allergy
|
GB0004889D0
(en)
|
2000-03-01 |
2000-04-19 |
Avecia Ltd |
Synthesis of oligonucleotides
|
EP1130091A3
(en)
|
2000-03-01 |
2001-11-14 |
Message Pharmaceuticals, Inc. |
Bacterial RNaseP Proteins and their use in identifying antibacterial compounds
|
WO2001070663A2
(en)
|
2000-03-17 |
2001-09-27 |
Corixa Corporation |
Novel amphipathic aldehydes and their use as adjuvants and immunoeffectors
|
DE10019756A1
(de)
|
2000-04-20 |
2001-10-25 |
Bayer Ag |
Verfahren zur Herstellung von superabsorbierenden Polymeren aus Polyacrylnitrilen
|
DE60105144T2
(de)
|
2000-04-20 |
2005-09-08 |
F. Hoffmann-La Roche Ag |
Pyrrolidin und piperidin derivate für die behandlung von neurodegenerativen erkrankungen
|
WO2001085751A1
(en)
|
2000-05-09 |
2001-11-15 |
Reliable Biopharmaceutical, Inc. |
Polymeric compounds useful as prodrugs
|
US6492171B2
(en)
|
2000-05-16 |
2002-12-10 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of TERT expression
|
US6725412B1
(en)
|
2000-08-15 |
2004-04-20 |
Dolby Laboratories Licensing Corporation |
Low latency data encoder
|
US6809195B1
(en)
|
2000-08-16 |
2004-10-26 |
Isis Pharmaceuticals, Inc. |
Process for the preparation of oligonucleotides
|
US6559279B1
(en)
|
2000-09-08 |
2003-05-06 |
Isis Pharmaceuticals, Inc. |
Process for preparing peptide derivatized oligomeric compounds
|
EP1191097A1
(en)
|
2000-09-21 |
2002-03-27 |
Leids Universitair Medisch Centrum |
Induction of exon skipping in eukaryotic cells
|
US6376190B1
(en)
|
2000-09-22 |
2002-04-23 |
Somalogic, Inc. |
Modified SELEX processes without purified protein
|
EP2351855A1
(en)
|
2000-09-26 |
2011-08-03 |
Duke University |
RNA aptamers and methods for identifying the same
|
GB0024752D0
(en)
|
2000-10-10 |
2000-11-22 |
Univ Belfast |
Oxidative halogenation of aromatic compounds
|
JP4176466B2
(ja)
|
2000-10-16 |
2008-11-05 |
ギリード・サイエンシズ・インコーポレーテッド |
前立腺特異的膜抗原に対する核酸リガンド
|
NZ525320A
(en)
|
2000-10-18 |
2004-10-29 |
Glaxosmithkline Biolog S |
Combinations of immunostimulatory oligonucleotides (CpG), saponin and optionally lipopolysaccharides as potent vaccine adjuvants
|
US6682889B1
(en)
|
2000-11-08 |
2004-01-27 |
Becton, Dickinson And Company |
Amplification and detection of organisms of the Chlamydiaceae family
|
JP2002165594A
(ja)
|
2000-11-29 |
2002-06-11 |
National Institute Of Advanced Industrial & Technology |
C型肝炎ウイルスのires及びns3プロテアーゼを標的とするrna分子
|
NL1016978C2
(nl)
|
2000-12-22 |
2002-06-25 |
Robert Jan Colenbrander |
Inrichting en werkwijze voor het verpakken en bereiden van voedsel en werkwijze voor het vervaardigen van een dergelijke inrichting.
|
HUP0400726A3
(en)
|
2001-01-22 |
2007-05-29 |
Merck & Co Inc |
Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
|
CA2474172C
(en)
|
2001-01-25 |
2012-07-10 |
Evolva Ltd. |
A library of a collection of cells
|
US8008459B2
(en)
|
2001-01-25 |
2011-08-30 |
Evolva Sa |
Concatemers of differentially expressed multiple genes
|
NZ526507A
(en)
|
2001-01-26 |
2005-07-29 |
Commw Scient Ind Res Org |
Methods and means for producing efficient silencing construct using recombinational cloning
|
EP1383782A1
(en)
|
2001-03-26 |
2004-01-28 |
Sirna Therpeutics, Inc. |
Oligonucleotide mediated inhibition of hepatitis b virus and hepatitis c virus replication
|
US20050277133A1
(en)
|
2001-05-18 |
2005-12-15 |
Sirna Therapeutics, Inc. |
RNA interference mediated treatment of polyglutamine (polyQ) repeat expansion diseases using short interfering nucleic acid (siNA)
|
US20030207804A1
(en)
|
2001-05-25 |
2003-11-06 |
Muthiah Manoharan |
Modified peptide nucleic acids
|
GB0113523D0
(en)
|
2001-06-04 |
2001-07-25 |
Torotrak Dev Ltd |
An Hydraulic control circuit for a continuosly variable transmission
|
US20030069410A1
(en)
|
2001-06-14 |
2003-04-10 |
Isis Pharmaceuticals, Inc. |
Methods for preparing oligonucleotides having chiral phosphorothioate linkages
|
CN1636015A
(zh)
|
2001-06-29 |
2005-07-06 |
希龙公司 |
Hcv e1e2疫苗组合物
|
JP2005504020A
(ja)
|
2001-07-03 |
2005-02-10 |
アイシス・ファーマシューティカルス・インコーポレーテッド |
ヌクレアーゼ耐性キメラオリゴヌクレオチド
|
US7205399B1
(en)
|
2001-07-06 |
2007-04-17 |
Sirna Therapeutics, Inc. |
Methods and reagents for oligonucleotide synthesis
|
US6440739B1
(en)
|
2001-07-17 |
2002-08-27 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of glioma-associated oncogene-2 expression
|
US7425545B2
(en)
|
2001-07-25 |
2008-09-16 |
Isis Pharmaceuticals, Inc. |
Modulation of C-reactive protein expression
|
US6455308B1
(en)
|
2001-08-01 |
2002-09-24 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of serum amyloid A4 expression
|
US7407943B2
(en)
|
2001-08-01 |
2008-08-05 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of apolipoprotein B expression
|
US7888324B2
(en)
|
2001-08-01 |
2011-02-15 |
Genzyme Corporation |
Antisense modulation of apolipoprotein B expression
|
US7259150B2
(en)
|
2001-08-07 |
2007-08-21 |
Isis Pharmaceuticals, Inc. |
Modulation of apolipoprotein (a) expression
|
US7227014B2
(en)
|
2001-08-07 |
2007-06-05 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of apolipoprotein (a) expression
|
AU2002361468A1
(en)
|
2001-08-14 |
2003-03-18 |
The Government Of The United States Of America As Represented By The Secretary Of Health And Human S |
Method for rapid generation of mature dendritic cells
|
EP1418877A2
(en)
|
2001-08-24 |
2004-05-19 |
Massachusetts Institute Of Technology |
Reagents that facilitate the purification of compounds synthesized on a solid support
|
US7049122B2
(en)
|
2001-09-21 |
2006-05-23 |
Academia Sinica |
Mutant-type lipases and applications thereof
|
US6933288B2
(en)
|
2002-02-04 |
2005-08-23 |
Isis Pharmaceuticals, Inc. |
Pyranosyl cytosines: pharmaceutical formulations and methods
|
JP4348044B2
(ja)
|
2002-02-12 |
2009-10-21 |
株式会社キラルジェン |
立体規則性の高いジヌクレオシドホスホロチオエートの製造法
|
US20050096284A1
(en)
|
2002-02-20 |
2005-05-05 |
Sirna Therapeutics, Inc. |
RNA interference mediated treatment of polyglutamine (polyQ) repeat expansion diseases using short interfering nucleic acid (siNA)
|
WO2003106476A1
(en)
|
2002-02-20 |
2003-12-24 |
Sirna Therapeutics, Inc |
Nucleic acid mediated inhibition of enterococcus infection and cytolysin toxin activity
|
US8232383B2
(en)
|
2002-02-20 |
2012-07-31 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
|
US7288376B2
(en)
|
2002-03-22 |
2007-10-30 |
Council Of Scientific And Industrial Research |
Method of detection of SP-A2 gene variants useful for prediction of predisposition to aspergillosis
|
US20040102394A1
(en)
|
2002-11-23 |
2004-05-27 |
Isis Pharmaceuticals Inc. |
Modulation of huntingtin interacting protein 2 expression
|
WO2003097662A1
(en)
|
2002-05-15 |
2003-11-27 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of apolipoprotein b expression
|
WO2003100017A2
(en)
|
2002-05-24 |
2003-12-04 |
Isis Pharmaceuticals, Inc. |
Oligonucleotides having modified nucleoside units
|
AU2003237249A1
(en)
|
2002-05-24 |
2003-12-12 |
Isis Pharmaceuticals, Inc. |
Oligonucleotides having modified nucleoside units
|
AU2003238772A1
(en)
|
2002-05-31 |
2003-12-19 |
Regents Of The University Of Minnesota |
In vitro evaluation of nucleic acid ligands
|
US7507808B2
(en)
|
2002-12-12 |
2009-03-24 |
Isis Pharmaceuticals, Inc. |
Modulation of endothelial lipase expression
|
WO2003106477A1
(en)
|
2002-06-01 |
2003-12-24 |
Isis Pharmaceuticals, Inc. |
Oligomeric compounds that include carbocyclic nucleosides and their use in gene modulation
|
US20040005338A1
(en)
|
2002-06-20 |
2004-01-08 |
Cytos Biotechnology Ag |
Packaged virus-like particles for use as adjuvants: method of preparation and use
|
WO2004003228A1
(en)
|
2002-07-01 |
2004-01-08 |
Unisearch Limited |
Genotyping method
|
US8101348B2
(en)
|
2002-07-10 |
2012-01-24 |
Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.V. |
RNA-interference by single-stranded RNA molecules
|
US20040023905A1
(en)
|
2002-07-31 |
2004-02-05 |
Isis Pharmaceuticals Inc. |
Antisense modulation of LAR expression
|
EP1386972A1
(en)
|
2002-08-01 |
2004-02-04 |
Noxxon Pharma AG |
Method and apparatus for designing a nucleic acid having a desired property
|
US20050255086A1
(en)
|
2002-08-05 |
2005-11-17 |
Davidson Beverly L |
Nucleic acid silencing of Huntington's Disease gene
|
US20080274989A1
(en)
|
2002-08-05 |
2008-11-06 |
University Of Iowa Research Foundation |
Rna Interference Suppression of Neurodegenerative Diseases and Methods of Use Thereof
|
US20050042646A1
(en)
|
2002-08-05 |
2005-02-24 |
Davidson Beverly L. |
RNA interference suppresion of neurodegenerative diseases and methods of use thereof
|
WO2004014933A1
(en)
|
2002-08-07 |
2004-02-19 |
University Of Massachusetts |
Compositions for rna interference and methods of use thereof
|
AR040996A1
(es)
|
2002-08-19 |
2005-04-27 |
Coley Pharm Group Inc |
Acidos nucleicos inmunoestimuladores
|
US7414116B2
(en)
|
2002-08-23 |
2008-08-19 |
Illumina Cambridge Limited |
Labelled nucleotides
|
KR101360955B1
(ko)
|
2002-09-13 |
2014-02-10 |
레플리코르 인코포레이티드 |
비서열 상보적 항바이러스 올리고뉴클레오티드
|
US7030230B2
(en)
|
2002-10-25 |
2006-04-18 |
Isis Pharmaceuticals, Inc. |
Process of purifying phosphoramidites
|
NZ540098A
(en)
|
2002-10-29 |
2008-09-26 |
Coley Pharmaceutical Group Ltd |
Use of CPG oligonucleotides in the treatment of hepatitis C virus infection
|
EP1562971B1
(en)
|
2002-11-05 |
2014-02-12 |
Isis Pharmaceuticals, Inc. |
Polycyclic sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation
|
WO2004044132A2
(en)
|
2002-11-05 |
2004-05-27 |
Isis Pharmaceuticals, Inc. |
Modified oligonucleotides for use in rna interference
|
AU2003291721A1
(en)
|
2002-11-05 |
2004-06-03 |
Isis Pharmaceuticals, Inc. |
Phosphorous-linked oligomeric compounds and their use in gene modulation
|
CA2505090A1
(en)
|
2002-11-05 |
2004-05-27 |
Isis Pharmaceuticals, Inc. |
Conjugated oligomeric compounds and their use in gene modulation
|
US7381527B2
(en)
|
2002-11-06 |
2008-06-03 |
Council Of Scientific And Industrial Research |
Method of detection of SP-A2 gene variants
|
US7511131B2
(en)
|
2002-11-13 |
2009-03-31 |
Genzyme Corporation |
Antisense modulation of apolipoprotein B expression
|
WO2004044181A2
(en)
|
2002-11-13 |
2004-05-27 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of apolipoprotein b expression
|
AU2003295600A1
(en)
|
2002-11-14 |
2004-06-15 |
Dharmacon, Inc. |
Functional and hyperfunctional sirna
|
EP2216407B1
(en)
|
2003-03-07 |
2016-01-13 |
Alnylam Pharmaceuticals, Inc. |
Therapeutic compositions
|
GB0305422D0
(en)
|
2003-03-10 |
2003-04-16 |
Univ Open |
Detection, monitoring and treatment of cancer
|
AU2003225410A1
(en)
|
2003-03-21 |
2004-10-11 |
Academisch Ziekenhuis Leiden |
Modulation of exon recognition in pre-mrna by interfering with the secondary rna structure
|
GB0306657D0
(en)
|
2003-03-24 |
2003-04-30 |
Avecia Ltd |
Process and compounds
|
US7537767B2
(en)
|
2003-03-26 |
2009-05-26 |
Cytis Biotechnology Ag |
Melan-A- carrier conjugates
|
ZA200507063B
(en)
|
2003-03-26 |
2007-03-28 |
Cytos Biotechnology Ag |
Packaging of immunostimulatory oligonucleotides into virus-like particles: Method of preparation and use
|
ITRM20030149A1
(it)
|
2003-04-02 |
2004-10-03 |
Giuliani Spa |
Oligonucleotidi (odn) antisenso per smad7 e loro usi in campo medico
|
US7598227B2
(en)
|
2003-04-16 |
2009-10-06 |
Isis Pharmaceuticals Inc. |
Modulation of apolipoprotein C-III expression
|
EP1620547B1
(en)
|
2003-04-21 |
2014-06-18 |
Archemix LLC |
Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics
|
US7045306B2
(en)
|
2003-04-28 |
2006-05-16 |
The General Hospital Corporation |
Method for identifying compounds in vitro that modulate the dysregulation of transcription of transcription mediated by mutant huntingtin protein
|
US7214491B2
(en)
|
2003-05-07 |
2007-05-08 |
E. I. Du Pont De Nemours And Company |
Δ-12 desaturase gene suitable for altering levels of polyunsaturated fatty acids in oleaginous yeasts
|
CA2526893C
(en)
|
2003-05-14 |
2010-10-26 |
Japan Science And Technology Agency |
Inhibition of the expression of huntingtin gene
|
BRPI0410886A
(pt)
|
2003-06-03 |
2006-07-04 |
Isis Pharmaceuticals Inc |
composto de filamento duplo, composição farmacêutica, sal farmaceuticamente aceitável, métodos de modificação do ácido nucleico que codifica a survivina humana, de inibição da expressão da suvivina em células ou tecidos, e de tratamento de uma condição associada com a expressão ou superexpressão da suvivina, e, oligonucleotìdeo de rnai de filamento único
|
JP2007524615A
(ja)
|
2003-06-20 |
2007-08-30 |
コーリー ファーマシューティカル ゲーエムベーハー |
低分子トール様レセプター(tlr)アンタゴニスト
|
US7683036B2
(en)
|
2003-07-31 |
2010-03-23 |
Regulus Therapeutics Inc. |
Oligomeric compounds and compositions for use in modulation of small non-coding RNAs
|
JP2011088935A
(ja)
|
2003-08-08 |
2011-05-06 |
Chiralgen Ltd |
リン原子修飾ヌクレオチド類縁体の製造のための光学活性ヌクレオシド3’−ホスホロアミダイト
|
JP2005089441A
(ja)
|
2003-08-08 |
2005-04-07 |
Toudai Tlo Ltd |
立体規則性の高いリン原子修飾ヌクレオチド類縁体の製造法
|
US7825235B2
(en)
|
2003-08-18 |
2010-11-02 |
Isis Pharmaceuticals, Inc. |
Modulation of diacylglycerol acyltransferase 2 expression
|
US7427672B2
(en)
|
2003-08-28 |
2008-09-23 |
Takeshi Imanishi |
Artificial nucleic acids of n-o bond crosslinkage type
|
JP4616175B2
(ja)
|
2003-09-02 |
2011-01-19 |
株式会社キラルジェン |
5’−ホスフィチル化モノマーおよびh−ホスホネートオリゴヌクレオチド誘導体の製造方法
|
WO2005023828A1
(ja)
|
2003-09-02 |
2005-03-17 |
Takeshi Wada |
リボヌクレオチド又はリボヌクレオチド誘導体の製造方法
|
PL1667522T3
(pl)
|
2003-09-09 |
2018-06-29 |
Geron Corporation |
Zmodyfikowane oligonukleotydy do hamowania telomerazy
|
US20050074801A1
(en)
|
2003-09-09 |
2005-04-07 |
Monia Brett P. |
Chimeric oligomeric compounds comprising alternating regions of northern and southern conformational geometry
|
US20050053981A1
(en)
|
2003-09-09 |
2005-03-10 |
Swayze Eric E. |
Gapped oligomeric compounds having linked bicyclic sugar moieties at the termini
|
US8680063B2
(en)
|
2003-09-12 |
2014-03-25 |
University Of Massachusetts |
RNA interference for the treatment of gain-of-function disorders
|
WO2008005562A2
(en)
|
2006-07-07 |
2008-01-10 |
University Of Massachusetts |
Rna silencing compositions and methods for the treatment of huntington's disease
|
EP2821085B1
(en)
|
2003-09-12 |
2020-04-29 |
University of Massachusetts |
Rna interference for the treatment of gain-of-function disorders
|
GB0323968D0
(en)
|
2003-10-13 |
2003-11-19 |
Glaxosmithkline Biolog Sa |
Immunogenic compositions
|
AU2004285561C1
(en)
|
2003-10-30 |
2012-06-21 |
Coley Pharmaceutical Gmbh |
C-class oligonucleotide analogs with enhanced immunostimulatory potency
|
US20050239102A1
(en)
|
2003-10-31 |
2005-10-27 |
Verdine Gregory L |
Nucleic acid binding oligonucleotides
|
US7846436B2
(en)
|
2003-11-28 |
2010-12-07 |
Chemgenes Corporation |
Oligonucleotides and related compounds
|
JP4945129B2
(ja)
|
2004-01-27 |
2012-06-06 |
株式会社キラルジェン |
フルオラス担体およびそれを用いたオリゴヌクレオチド誘導体の製造方法
|
US20050176045A1
(en)
|
2004-02-06 |
2005-08-11 |
Dharmacon, Inc. |
SNP discriminatory siRNA
|
EP1725250A2
(en)
|
2004-02-18 |
2006-11-29 |
Frutarom Ltd. |
Method for the preparation of peptide-oligonucleotide conjugates
|
JP3976742B2
(ja)
|
2004-02-27 |
2007-09-19 |
江守商事株式会社 |
インターフェロンアルファを誘導する免疫刺激オリゴヌクレオチド
|
WO2005085272A1
(ja)
|
2004-03-05 |
2005-09-15 |
Takeshi Wada |
ボラノホスフェートモノマーおよびそれを用いたオリゴヌクレオチド誘導体の製造方法
|
US20060193821A1
(en)
|
2004-03-05 |
2006-08-31 |
Diener John L |
Aptamers to the human IL-12 cytokine family and their use as autoimmune disease therapeutics
|
JP4865544B2
(ja)
|
2004-03-25 |
2012-02-01 |
株式会社キラルジェン |
立体規則性の高いリボヌクレオチド類縁体及びデオキシリボヌクレオチド類縁体の製造法
|
JP2007531794A
(ja)
|
2004-04-05 |
2007-11-08 |
アルニラム ファーマスーティカルズ インコーポレイテッド |
オリゴヌクレオチドの合成および精製に使用する方法および反応試薬
|
US20050244869A1
(en)
|
2004-04-05 |
2005-11-03 |
Brown-Driver Vickie L |
Modulation of transthyretin expression
|
CA2564311A1
(en)
|
2004-04-26 |
2005-12-01 |
Sharon Cload |
Nucleic acid ligands specific to immunoglobulin e and their use as atopic disease therapeutics
|
TWI350168B
(en)
|
2004-05-07 |
2011-10-11 |
Incyte Corp |
Amido compounds and their use as pharmaceuticals
|
EP1753881A2
(en)
|
2004-05-27 |
2007-02-21 |
The Government of the United States of America as represented by The Secretary of the Department of Health and Human Services |
Differential expression of molecules associated with acute stroke
|
US7759318B1
(en)
|
2004-05-28 |
2010-07-20 |
Isis Pharmaceuticals, Inc. |
Identification of novel pathways, genes and promoter motifs regulating adipogenesis
|
JP2008501693A
(ja)
|
2004-06-03 |
2008-01-24 |
アイシス ファーマシューティカルズ、インク. |
遺伝子調節で使用するための個別に調節された鎖を有する二本鎖組成物
|
EP3228711A1
(en)
|
2004-06-28 |
2017-10-11 |
The University Of Western Australia |
Antisense oligonucleotides for inducing exon skipping and methods of use thereof
|
EP1786472B1
(en)
|
2004-08-10 |
2013-01-16 |
Genzyme Corporation |
Antisense modulation of apolipoprotein b expression
|
JP5157168B2
(ja)
|
2004-08-26 |
2013-03-06 |
日本新薬株式会社 |
ホスホロアミダイト化合物及びオリゴrnaの製法
|
US20070066551A1
(en)
|
2004-09-07 |
2007-03-22 |
Keefe Anthony D |
Aptamer medicinal chemistry
|
CA2579374A1
(en)
|
2004-09-07 |
2006-03-30 |
Archemix Corp. |
Aptamers to von willebrand factor and their use as thrombotic disease therapeutics
|
US7884086B2
(en)
|
2004-09-08 |
2011-02-08 |
Isis Pharmaceuticals, Inc. |
Conjugates for use in hepatocyte free uptake assays
|
WO2006031461A2
(en)
|
2004-09-09 |
2006-03-23 |
Isis Pharmaceuticals, Inc. |
Pyrrolidinyl groups for attaching conjugates to oligomeric compounds
|
AU2005286738A1
(en)
|
2004-09-17 |
2006-03-30 |
Isis Pharmaceuticals, Inc. |
Enhanced antisense oligonucleotides
|
AU2005295756B2
(en)
|
2004-10-13 |
2012-02-02 |
Isis Parmaceuticals, Inc. |
Antisense modulation of PTP1B expression
|
KR100721928B1
(ko)
|
2004-11-05 |
2007-05-28 |
주식회사 바이오씨에스 |
CpG 올리고데옥시뉴클레오티드를 함유하는 피부질환의치료 또는 예방용 약학적 조성물
|
EP1657307A1
(en)
|
2004-11-16 |
2006-05-17 |
Immunotech S.A. |
Oligonucleotides that induce the secretion of GM-CSF
|
AU2005313883B2
(en)
|
2004-12-09 |
2011-03-31 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inducing an immune response in a mammal and methods of avoiding an immune response to oligonucleotide agents such as short interfering RNAs
|
WO2006065751A2
(en)
|
2004-12-13 |
2006-06-22 |
Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services |
Cpg oligonucleotide prodrugs, compositions thereof and associated therapeutic methods
|
WO2006066260A2
(en)
|
2004-12-17 |
2006-06-22 |
Thiosense, Inc. |
Compositions of and methods for producing phosphorus-chiral monomers and oligomers
|
US20060183763A1
(en)
|
2004-12-31 |
2006-08-17 |
Pfizer Inc |
Novel pyrrolidyl derivatives of heteroaromatic compounds
|
US20060166901A1
(en)
|
2005-01-03 |
2006-07-27 |
Yu Ruey J |
Compositions comprising O-acetylsalicyl derivatives of aminocarbohydrates and amino acids
|
JP4836145B2
(ja)
|
2005-01-28 |
2011-12-14 |
クウォン,ヒュン−ジョ |
マイコバクテリアに由来する、免疫機能刺激用、免疫疾患治療用、アトピー性皮膚炎治療用および/または正常免疫細胞保護用オリゴヌクレオチド
|
US20080009455A9
(en)
|
2005-02-24 |
2008-01-10 |
Coley Pharmaceutical Group, Inc. |
Immunostimulatory oligonucleotides
|
JP2006248949A
(ja)
|
2005-03-09 |
2006-09-21 |
Univ Nagoya |
ヌクレオシド誘導体、ヌクレオチド誘導体及びそれらの製造方法
|
EP1866319B1
(en)
|
2005-04-01 |
2011-11-23 |
The Regents of The University of California |
Phosphono-pent-2-en-1-yl nucleosides and analogs
|
ZA200709237B
(en)
|
2005-05-05 |
2009-04-29 |
Antisense Pharma Gmbh |
Dosage of oligonucleotides
|
US7902352B2
(en)
|
2005-05-06 |
2011-03-08 |
Medtronic, Inc. |
Isolated nucleic acid duplex for reducing huntington gene expression
|
WO2006121960A2
(en)
|
2005-05-06 |
2006-11-16 |
Medtronic, Inc. |
Methods and sequences to suppress primate huntington gene expression
|
WO2006138676A2
(en)
|
2005-06-15 |
2006-12-28 |
The Ohio State University Research Foundation |
Aptamers that bind to prion protein
|
US10242753B2
(en)
|
2005-06-17 |
2019-03-26 |
University Of Washington |
Method for measuring strength of associations of multidimensional traits
|
ES2397113T3
(es)
|
2005-06-23 |
2013-03-04 |
Isis Pharmaceuticals, Inc. |
Composiciones y procedimientos para modular el corte y empalme de SMN2
|
EP2322657B1
(en)
|
2005-06-28 |
2014-11-05 |
Medtronic, Inc. |
Methods and sequences to preferentially suppress expression of mutated huntingtin gene.
|
US9133517B2
(en)
|
2005-06-28 |
2015-09-15 |
Medtronics, Inc. |
Methods and sequences to preferentially suppress expression of mutated huntingtin
|
EP1948600B1
(en)
|
2005-07-05 |
2014-04-16 |
The President & Fellows Of Harvard College |
Liver targeted conjugates
|
JP4984634B2
(ja)
|
2005-07-21 |
2012-07-25 |
ソニー株式会社 |
物理情報取得方法および物理情報取得装置
|
WO2007016379A2
(en)
|
2005-07-28 |
2007-02-08 |
Id-Fish Technology, Inc. |
Method for improving cell permeability to foreign particles
|
WO2007025049A2
(en)
|
2005-08-26 |
2007-03-01 |
Archemix Corp. |
Aptamers that bind thrombin with high affinity
|
ATE494372T1
(de)
|
2005-08-29 |
2011-01-15 |
Regulus Therapeutics Inc |
Verfahren für mir-122a-modulation
|
EP1937312B1
(en)
*
|
2005-08-30 |
2016-06-29 |
Ionis Pharmaceuticals, Inc. |
Chimeric oligomeric compounds for modulation of splicing
|
EP1931803A2
(en)
|
2005-09-15 |
2008-06-18 |
Duke University |
Focused libraries, functional profiling, laser selex and deselex
|
US7700567B2
(en)
|
2005-09-29 |
2010-04-20 |
Supergen, Inc. |
Oligonucleotide analogues incorporating 5-aza-cytosine therein
|
US20070077993A1
(en)
|
2005-09-30 |
2007-04-05 |
Midgley Timothy M |
Method and apparatus for collecting user game play data and crediting users in a gaming environment
|
US8357665B2
(en)
|
2005-10-12 |
2013-01-22 |
Idera Pharmaceuticals, Inc. |
Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response
|
US9308252B2
(en)
|
2005-10-27 |
2016-04-12 |
Cook Biotech, Inc. |
Extracellular matrix materials as vaccine adjuvants for diseases associated with infectious pathogens or toxins
|
US7320965B2
(en)
|
2005-10-28 |
2008-01-22 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of Huntingtin gene
|
WO2007049416A1
(ja)
|
2005-10-28 |
2007-05-03 |
Tosoh Corporation |
カロテノイド合成微生物の作製方法およびカロテノイドの製造方法
|
BRPI0618473A2
(pt)
|
2005-11-11 |
2011-08-30 |
Pfizer |
combinações e métodos de uso de um oligodeoxinucleotìdeo imunomodulador
|
WO2007064291A1
(en)
|
2005-11-30 |
2007-06-07 |
Jyoti Chattopadhyaya |
Method and compounds for rna synthesis
|
JP5256043B2
(ja)
|
2005-12-02 |
2013-08-07 |
アイシス ファーマシューティカルズ, インコーポレーテッド |
複数の置換基を有する抗菌4,5−置換アミノグリコシドアナログ
|
US8076303B2
(en)
|
2005-12-13 |
2011-12-13 |
Spring Bank Pharmaceuticals, Inc. |
Nucleotide and oligonucleotide prodrugs
|
DK1979356T3
(da)
|
2005-12-21 |
2013-11-18 |
Pfizer Prod Inc |
Carbonylaminopyrrolopyrazoler, kraftige kinaseinhibitorer
|
CA2638908C
(en)
|
2006-01-26 |
2021-04-27 |
Susan M. Freier |
Compositions and their uses directed to huntingtin
|
CN102908630B
(zh)
|
2006-01-27 |
2014-11-19 |
Isis制药公司 |
6-修饰的双环核酸类似物
|
BRPI0707842B8
(pt)
|
2006-02-14 |
2023-04-18 |
Noxxon Pharma Ag |
Ácido nucleico capaz de se ligar à mcp-1, seus usos, seu método de detecção, bem como composição farmacêutica, complexo, método para a triagem de um antagonista de quimiocina ou um agonista de quimiocina e kit para a detecção de uma quimiocina
|
JP5473336B2
(ja)
|
2006-02-15 |
2014-04-16 |
アディウタイド・ファーマスーティカルズ・ゲーエムベーハー |
オリゴヌクレオチドの処方に関する組成物および方法
|
NZ571791A
(en)
|
2006-03-08 |
2012-03-30 |
Archemix Llc |
Complement binding aptamers and anti-C5 agents useful in the treatment of ocular disorders
|
US8383660B2
(en)
|
2006-03-10 |
2013-02-26 |
Pfizer Inc. |
Dibenzyl amine compounds and derivatives
|
EP2001871B1
(en)
|
2006-03-31 |
2014-07-16 |
Applied Biosystems, LLC |
Rhodamine-labeled oligonucleotides
|
US8088582B2
(en)
|
2006-04-06 |
2012-01-03 |
Ibis Biosciences, Inc. |
Compositions for the use in identification of fungi
|
DE602007008222D1
(de)
|
2006-04-20 |
2010-09-16 |
Hoffmann La Roche |
Diazepanderivate als modulatoren von chemokinrezeptoren
|
WO2007123386A1
(es)
|
2006-04-24 |
2007-11-01 |
Sigma Alimentos, S.A. De C.V. |
Método para la detección y cuantificación múltiple y simultánea de patógenos mediante la reacción en cadena de la polimerasa en tiempo real
|
AU2007243412A1
(en)
|
2006-04-25 |
2007-11-08 |
Immune Disease Institute Inc. |
Targeted delivery to leukocytes using non-protein carriers
|
GB0608838D0
(en)
|
2006-05-04 |
2006-06-14 |
Novartis Ag |
Organic compounds
|
US8158598B2
(en)
|
2006-05-05 |
2012-04-17 |
Isis Pharmaceuticals, Inc. |
Compositions and their uses directed to PTPR alpha
|
AU2007257093A1
(en)
|
2006-05-05 |
2007-12-13 |
Isis Pharmaceuticals, Inc. |
Compounds and methods for modulating expression of PCSK9
|
US20090012120A1
(en)
|
2006-05-10 |
2009-01-08 |
Board Of Trustees Of Michigan State University |
Synthesis of N-heterocycles, beta-amino acids, and allyl amines via aza-payne mediated reaction of ylides and hydroxy aziridines
|
US7666854B2
(en)
|
2006-05-11 |
2010-02-23 |
Isis Pharmaceuticals, Inc. |
Bis-modified bicyclic nucleic acid analogs
|
EP2066684B1
(en)
|
2006-05-11 |
2012-07-18 |
Isis Pharmaceuticals, Inc. |
5'-modified bicyclic nucleic acid analogs
|
US20090048193A1
(en)
|
2006-05-26 |
2009-02-19 |
Rusconi Christopher P |
Administration of the REG1 anticoagulation system
|
PL2034015T3
(pl)
|
2006-05-31 |
2012-11-30 |
Toray Industries |
Immunostymulujący oligonukleotyd i jego zastosowanie farmaceutyczne
|
US8097596B2
(en)
|
2006-06-30 |
2012-01-17 |
Lakewood-Amedex, Inc. |
Compositions and methods for the treatment of muscle wasting
|
US9233106B2
(en)
|
2006-07-12 |
2016-01-12 |
Cornell Research Foundation, Inc. |
Inhibition of beta-amyloid peptide aggregation
|
CN101506368B
(zh)
|
2006-07-12 |
2017-02-08 |
加利福尼亚大学董事会 |
通过可逆的磷酸三酯电荷中和保护基转导运输核酸
|
CN101506364B
(zh)
|
2006-07-18 |
2013-10-30 |
诺松制药股份公司 |
Sdf-1结合性核酸
|
AU2007275301A1
(en)
|
2006-07-20 |
2008-01-24 |
Amgen Inc. |
Substituted azole aromatic heterocycles as inhibitors of 11-beta-HSD-1
|
CN100503824C
(zh)
|
2006-07-20 |
2009-06-24 |
武汉大学 |
抗结核杆菌感染的小分子核苷酸dna适配子及其制备方法
|
AU2007281082A1
(en)
|
2006-08-04 |
2008-02-07 |
Isis Pharmaceuticals, Inc. |
Compositions and methods for the modulation of JNK proteins
|
AT504194B1
(de)
|
2006-09-07 |
2008-07-15 |
Oesterr Rotes Kreuz |
Bakteriennachweis
|
EP1897562A1
(en)
|
2006-09-08 |
2008-03-12 |
Bayer Schering Pharma Aktiengesellschaft |
Aptamers labelled with Gallium-68
|
US8138330B2
(en)
|
2006-09-11 |
2012-03-20 |
Sigma-Aldrich Co. Llc |
Process for the synthesis of oligonucleotides
|
KR101251707B1
(ko)
|
2006-09-27 |
2013-04-11 |
콜리 파마슈티칼 게엠베하 |
면역 자극 활성이 증강된 소수성 T 유사체를 함유하는 CpG 올리고뉴클레오티드 유사체
|
EP2410054B2
(en)
|
2006-10-18 |
2019-12-11 |
Ionis Pharmaceuticals, Inc. |
Antisense compounds
|
CA2667816A1
(en)
|
2006-10-23 |
2008-05-02 |
Irm Llc |
Compositions and methods for inhibiting cathepsin proteases
|
KR20090058584A
(ko)
|
2006-10-26 |
2009-06-09 |
콜리 파마슈티칼 게엠베하 |
올리고리보뉴클레오티드 및 그의 용도
|
FR2908414B1
(fr)
|
2006-11-13 |
2012-01-20 |
Centre Nat Rech Scient |
Immobilisation de proteines membranaires sur un support par l'intermediaire d'une molecule amphiphile
|
MX2009005252A
(es)
|
2006-11-17 |
2009-05-28 |
Abbott Lab |
Aminopirrolidinas como antagonistas del receptor de quimiocina.
|
EP2455471A3
(en)
|
2006-11-27 |
2012-09-12 |
Isis Pharmaceuticals, Inc. |
Methods for treating hypercholesterolemia
|
US8093222B2
(en)
|
2006-11-27 |
2012-01-10 |
Isis Pharmaceuticals, Inc. |
Methods for treating hypercholesterolemia
|
KR100861108B1
(ko)
|
2006-11-28 |
2008-09-30 |
(주) 벡스코아 |
씨형 간염 바이러스 레플리콘 증식을 억제하는 알엔에이분해효소 저항성 알엔에이 압타머
|
JP2010512421A
(ja)
|
2006-12-12 |
2010-04-22 |
イデラ ファーマシューティカルズ インコーポレイテッド |
Tlr9の合成アゴニスト
|
UY30892A1
(es)
|
2007-02-07 |
2008-09-02 |
Smithkline Beckman Corp |
Inhibidores de la actividad akt
|
WO2008101157A1
(en)
|
2007-02-15 |
2008-08-21 |
Isis Pharmaceuticals, Inc. |
5'-substituted-2'-f modified nucleosides and oligomeric compounds prepared therefrom
|
CN103480002A
(zh)
|
2007-03-24 |
2014-01-01 |
基酶有限公司 |
施用与人载脂蛋白 b互补的反义寡核苷酸
|
EP2152722B1
(en)
|
2007-05-03 |
2016-04-27 |
Merck Sharp & Dohme Corp. |
Compositions comprising mir34 therapeutic agents for treating cancer
|
WO2008141308A2
(en)
|
2007-05-11 |
2008-11-20 |
Adynxx, Inc. |
Gene expression and pain
|
CA2688008A1
(en)
|
2007-05-24 |
2008-11-27 |
Kyorin Pharmaceutical Co., Ltd. |
Mutilin derivative having heterocyclic aromatic ring carboxylic acid structure in substituent at 14-position
|
GB0710186D0
(en)
|
2007-05-29 |
2007-07-04 |
Texas Instr Denmark |
PWM loop with minimum allasing error property
|
US8278425B2
(en)
|
2007-05-30 |
2012-10-02 |
Isis Pharmaceuticals, Inc. |
N-substituted-aminomethylene bridged bicyclic nucleic acid analogs
|
UA98783C2
(en)
|
2007-06-05 |
2012-06-25 |
Нсаб, Филиал Аф Ньюросерч Свиден Аб, Свериге |
Disubstituted phenylpyrrolidines as modulators of cortical catecholaminergic neurotransmission
|
WO2008154401A2
(en)
|
2007-06-08 |
2008-12-18 |
Isis Pharmaceuticals, Inc. |
Carbocyclic bicyclic nucleic acid analogs
|
US20100298280A1
(en)
|
2007-06-13 |
2010-11-25 |
Petra Kioschis-Schneider |
Compounds for the Modulation of Huntingtin Aggregation, Methods and Means for Identifying Such Compounds
|
EP2014769B1
(en)
|
2007-06-18 |
2010-03-31 |
Commissariat à l'Energie Atomique |
Reversible siRNAa-based silencing of mutated and endogenous wild-type huntingtin gene and its application for the treatment of Huntington's disease
|
DK2176280T4
(en)
|
2007-07-05 |
2015-07-20 |
Isis Pharmaceuticals Inc |
6-Disubstituerede bicykliske nukleinsyreanaloge
|
CA2692161C
(en)
|
2007-07-09 |
2015-09-29 |
Idera Pharmaceuticals, Inc. |
Stabilized immune modulatory rna (simra) compounds
|
WO2009015479A1
(en)
|
2007-07-31 |
2009-02-05 |
University Of Saskatchewan |
Genetic variation in pro-melanin-concentrating hormone gene affects carcass traits in cattle
|
EP2185700A4
(en)
|
2007-08-02 |
2010-11-24 |
Texas A & M Univ Sys |
ANTISENSE MICRO RNA AND USES THEREOF
|
JP2010536787A
(ja)
|
2007-08-15 |
2010-12-02 |
イデラ ファーマシューティカルズ インコーポレイテッド |
Toll様受容体モジュレータ
|
US8486904B2
(en)
|
2007-10-01 |
2013-07-16 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of fibroblast growth factor receptor 4 expression
|
KR100886139B1
(ko)
|
2007-11-13 |
2009-02-27 |
주식회사 삼천리제약 |
올리고뉴클레오타이드의 제조방법
|
AR069869A1
(es)
|
2007-12-21 |
2010-02-24 |
Exelixis Inc |
Derivados de benzofuro[3,2-d]pirimidinas inhibidores de proteinquinasas,composiciones farmaceuticas que los comprenden y usos de los mismos en el tratamiento del cancer.
|
TWI340765B
(en)
|
2007-12-26 |
2011-04-21 |
Ind Tech Res Inst |
Oligonucleotide sequences and dna chip for identifying filamentous microorganisms and the identification method thereof
|
US20100309376A1
(en)
|
2008-01-15 |
2010-12-09 |
Yungchun Lei |
Multimedia Presenting System, Multimedia Processing Apparatus Thereof, and Method for Presenting Video and Audio Signals
|
WO2009089659A1
(en)
|
2008-01-18 |
2009-07-23 |
Shanghai Targetdrug Co., Ltd. |
Pyrollidine-based compounds
|
CA2711587A1
(en)
|
2008-02-04 |
2009-08-13 |
Galapagos Nv |
Target sequences and methods to identify the same, useful in treatment of neurodegenerative diseases
|
JP2009190983A
(ja)
|
2008-02-12 |
2009-08-27 |
Tokyo Institute Of Technology |
オリゴヌクレオチド誘導体
|
US8426378B2
(en)
|
2008-03-21 |
2013-04-23 |
Isis Pharmaceuticals, Inc. |
Oligomeric compounds comprising tricyclic nucelosides and methods for their use
|
WO2009120878A2
(en)
|
2008-03-26 |
2009-10-01 |
Alnylam Pharmaceuticals, Inc. |
Non-natural ribonucleotides, and methods of use thereof
|
EP2271351A4
(en)
|
2008-04-03 |
2016-08-31 |
Spring Bank Pharmaceuticals Inc |
COMPOSITIONS AND METHODS FOR TREATING VIRAL INFECTIONS
|
WO2009124238A1
(en)
|
2008-04-04 |
2009-10-08 |
Isis Pharmaceuticals, Inc. |
Oligomeric compounds comprising neutrally linked terminal bicyclic nucleosides
|
CA2726866A1
(en)
|
2008-05-09 |
2009-11-12 |
The University Of British Columbia |
Methods and compositions for the treatment of huntington's disease
|
US8679750B2
(en)
|
2008-05-09 |
2014-03-25 |
The University Of British Columbia |
Methods and compositions for the treatment of Huntington'S disease
|
US8541388B2
(en)
|
2008-05-22 |
2013-09-24 |
Isis Pharmaceuticals, Inc. |
Methods for modulating expression of RBP4
|
US8541387B2
(en)
|
2008-05-22 |
2013-09-24 |
Isis Pharmaceuticals, Inc. |
Modulation of SMRT expression
|
WO2009143391A2
(en)
|
2008-05-22 |
2009-11-26 |
Isis Pharmaceuticals, Inc |
Methods for modulation expression of creb
|
WO2009148605A2
(en)
|
2008-06-04 |
2009-12-10 |
Isis Pharmaceuticals, Inc. |
Methods for treating hypercholesterolemia
|
CA2728559A1
(en)
|
2008-07-03 |
2010-01-07 |
Exelixis Inc. |
Cdk modulators
|
EP2346883B1
(en)
|
2008-09-23 |
2016-03-23 |
Scott G. Petersen |
Self delivering bio-labile phosphate protected pro-oligos for oligonucleotide based therapeutics and mediating rna interference
|
WO2010036698A1
(en)
|
2008-09-24 |
2010-04-01 |
Isis Pharmaceuticals, Inc. |
Substituted alpha-l-bicyclic nucleosides
|
DK2361256T3
(da)
|
2008-09-24 |
2013-07-01 |
Isis Pharmaceuticals Inc |
Cyclohexenyl-nukleinsyreanaloger
|
CA2739788A1
(en)
|
2008-10-07 |
2010-04-15 |
President And Fellows Of Harvard College |
Telomerase inhibitors that bind to the cr4-cr5 domain of the rna component of human telomerase and methods of use thereof
|
CA2962219C
(en)
|
2008-10-22 |
2020-08-25 |
Quark Pharmaceuticals, Inc. |
Methods for treating eye disorders
|
US20120059045A1
(en)
|
2008-10-24 |
2012-03-08 |
Isis Pharmaceuticals, Inc. |
Methods of using oligomeric compounds comprising 2'-substituted nucleosides
|
WO2010064146A2
(en)
*
|
2008-12-02 |
2010-06-10 |
Chiralgen, Ltd. |
Method for the synthesis of phosphorus atom modified nucleic acids
|
EP2382227A1
(en)
|
2008-12-23 |
2011-11-02 |
Girindus America, Inc. |
Sulfurizing reagents and their use for oligonucleotides synthesis
|
WO2010080953A1
(en)
|
2009-01-08 |
2010-07-15 |
Isis Pharmaceuticals, Inc. |
Transgenic murine model of human lipoprotein metabolism, hypercholesterolemia and cardiovascular disease
|
WO2010091301A1
(en)
|
2009-02-06 |
2010-08-12 |
Isis Pharmaceuticals, Inc. |
Oligomeric compounds and excipients
|
CA2752694A1
(en)
|
2009-02-10 |
2010-08-19 |
Idera Pharmaceuticals, Inc. |
Synthetic rna-based agonists of tlr7
|
EP2403863B1
(en)
|
2009-03-02 |
2013-08-28 |
Alnylam Pharmaceuticals Inc. |
Nucleic acid chemical modifications
|
EP2408796B1
(en)
|
2009-03-16 |
2020-04-22 |
Ionis Pharmaceuticals, Inc. |
Targeting Apolipoprotein B for the reduction of Apolipoprotein C-III
|
WO2010118263A1
(en)
|
2009-04-08 |
2010-10-14 |
University Of Massachusetts |
Single-nucleotide polymorphism (snp) targeting therapies for the treatment of huntington's disease
|
WO2010120262A1
(en)
|
2009-04-14 |
2010-10-21 |
Smith Holdings, Llc |
Methods and compositions for the treatment of medical conditions involving cellular programming
|
WO2010129853A2
(en)
|
2009-05-07 |
2010-11-11 |
The Regents Of The University Of California |
TRANSDUCIBLE DELIVERY OF NUCLEIC ACIDS USING MODIFIED dsRNA BINDING DOMAINS
|
CN102459302A
(zh)
|
2009-06-01 |
2012-05-16 |
加利福尼亚大学董事会 |
核酸递送组合物及其使用方法
|
PT2437753T
(pt)
|
2009-06-05 |
2016-11-23 |
Infectious Disease Res Inst |
Adjuvantes lipídicos de glucopiranosilo sintéticos e composições de vacina contendo os mesmos
|
RU2566724C9
(ru)
|
2009-06-17 |
2019-03-12 |
Байоджен Ma Инк. |
Композиции и способы модуляции smn2 сплайсинга у субъекта
|
KR101885383B1
(ko)
*
|
2009-07-06 |
2018-08-03 |
웨이브 라이프 사이언시스 리미티드 |
신규한 핵산 프로드러그 및 그의 사용 방법
|
US8329024B2
(en)
|
2009-07-06 |
2012-12-11 |
Ada Technologies, Inc. |
Electrochemical device and method for long-term measurement of hypohalites
|
US8927513B2
(en)
|
2009-07-07 |
2015-01-06 |
Alnylam Pharmaceuticals, Inc. |
5′ phosphate mimics
|
US20110009477A1
(en)
|
2009-07-08 |
2011-01-13 |
Idera Pharmaceuticals, Inc. |
Oligonucleotide-based compounds as inhibitors of toll-like receptors
|
WO2011015572A1
(en)
|
2009-08-03 |
2011-02-10 |
Galapagos Nv |
Molecular targets and compounds, and methods to identify the same, useful in the treatment of neurodegenerative diseases
|
WO2011015573A1
(en)
|
2009-08-03 |
2011-02-10 |
Galapagos Nv |
Molecular targets and compounds, and methods to identify the same, useful in the treatment of neurodegenerative diseases
|
EP2462153B1
(en)
|
2009-08-06 |
2015-07-29 |
Isis Pharmaceuticals, Inc. |
Bicyclic cyclohexose nucleic acid analogs
|
US8927553B2
(en)
|
2009-08-10 |
2015-01-06 |
Daljit Singh Dhanoa |
Deuterium-enriched alkyl sulfonamides and uses thereof
|
JP5809146B2
(ja)
|
2009-09-11 |
2015-11-10 |
アイシス ファーマシューティカルズ, インコーポレーテッド |
ハンチンチン発現の修飾
|
US8470987B2
(en)
|
2009-09-16 |
2013-06-25 |
Chiralgen, Ltd. |
Protective group for synthesis of RNA and derivative
|
US20120270929A1
(en)
|
2009-09-25 |
2012-10-25 |
Isis Pharmaceuticals, Inc. |
Modulation of ttc39 expression to increase hdl
|
MX2012004379A
(es)
|
2009-10-15 |
2012-06-01 |
Pfizer |
Compuestos de pirrolo[2,3-d]pirimidina.
|
US8735417B2
(en)
|
2009-12-17 |
2014-05-27 |
Merck Sharp & Dohme Corp. |
Aminopyrimidines as Syk inhibitors
|
MX2012007477A
(es)
|
2009-12-28 |
2012-11-29 |
Achira Labs Pvt Ltd |
Composicion de gel de diagnostico, metodo para hacer una composicion de gel de diagnostico.
|
CN106146591B
(zh)
|
2010-01-08 |
2020-07-31 |
Ionis制药公司 |
血管生成素样3表达的调节
|
US8750507B2
(en)
|
2010-01-25 |
2014-06-10 |
Cisco Technology, Inc. |
Dynamic group creation for managed key servers
|
EP2534248B1
(en)
|
2010-02-08 |
2018-08-29 |
Ionis Pharmaceuticals, Inc. |
Selective reduction of allelic variants
|
CA2789038A1
(en)
|
2010-02-08 |
2011-08-11 |
Isis Pharmaceuticals, Inc. |
Selective reduction of allelic variants
|
ES2525826T3
(es)
|
2010-02-10 |
2014-12-30 |
Glaxosmithkline Llc |
Maleato de 6-amino-2-{[(1s)-1-metilbutil]-oxi}-9-[5-(1-piperidinil)pentil]-7,9-dihidro-8H-purin-8-ona
|
CN102918052A
(zh)
|
2010-03-05 |
2013-02-06 |
国立大学法人东京大学 |
硫代磷酸核糖核苷的制造方法
|
WO2011127175A1
(en)
|
2010-04-06 |
2011-10-13 |
Isis Pharmaceuticals, Inc. |
Modulation of cd130 (gp130) expression
|
CA2795750A1
(en)
|
2010-04-07 |
2011-10-13 |
Isis Pharmaceuticals, Inc. |
Modulation of cetp expression
|
WO2011133871A2
(en)
|
2010-04-22 |
2011-10-27 |
Alnylam Pharmaceuticals, Inc. |
5'-end derivatives
|
EP3091027B1
(en)
|
2010-04-28 |
2018-01-17 |
Ionis Pharmaceuticals, Inc. |
5' modified nucleosides and oligomeric compounds prepared therefrom
|
KR101869570B1
(ko)
|
2010-04-28 |
2018-06-20 |
아이오니스 파마수티컬즈, 인코포레이티드 |
변형된 뉴클레오사이드 및 그로부터 제조된 올리고머 화합물
|
US20130156845A1
(en)
|
2010-04-29 |
2013-06-20 |
Alnylam Pharmaceuticals, Inc. |
Lipid formulated single stranded rna
|
GB201008902D0
(en)
|
2010-05-27 |
2010-07-14 |
Imp Innovations Ltd |
Membrane enhanced polymer sythesis
|
KR20130100278A
(ko)
|
2010-08-31 |
2013-09-10 |
머크 샤프 앤드 돔 코포레이션 |
올리고뉴클레오티드의 전달을 위한 신규 단일 화학 존재물 및 방법
|
EP2620428B1
(en)
|
2010-09-24 |
2019-05-22 |
Wave Life Sciences Ltd. |
Asymmetric auxiliary group
|
US9238812B2
(en)
|
2010-09-30 |
2016-01-19 |
Lsip, Llc |
Agent for suppressing expression of dominant mutant gene
|
KR101381048B1
(ko)
|
2010-10-20 |
2014-04-14 |
씨제이제일제당 (주) |
O-포스포세린 생산 균주 및 이로부터 생산된 o-포스포세린으로부터 l-시스테인 또는 이의 유도체의 생산방법
|
EP2633046A4
(en)
*
|
2010-10-29 |
2015-05-06 |
Alnylam Pharmaceuticals Inc |
COMPOSITIONS AND METHODS FOR INHIBITING PCSK9 GENES
|
EP3327125B1
(en)
|
2010-10-29 |
2020-08-05 |
Sirna Therapeutics, Inc. |
Rna interference mediated inhibition of gene expression using short interfering nucleic acids (sina)
|
EP3702460A1
(en)
|
2010-11-12 |
2020-09-02 |
The General Hospital Corporation |
Polycomb-associated non-coding rnas
|
US8822671B2
(en)
|
2010-11-30 |
2014-09-02 |
The University Of Tokyo |
2'-O-modified RNA
|
EP3067421B1
(en)
|
2011-02-08 |
2018-10-10 |
Ionis Pharmaceuticals, Inc. |
Oligomeric compounds comprising bicyclic nucleotides and uses thereof
|
ES2739804T3
(es)
|
2011-02-12 |
2020-02-04 |
Univ Iowa Res Found |
Compuestos terapéuticos
|
WO2012151324A1
(en)
|
2011-05-02 |
2012-11-08 |
Isis Pharmaceuticals, Inc. |
Antisense compounds targeting genes associated with usher syndrome
|
FR2975600B1
(fr)
|
2011-05-24 |
2013-07-05 |
Assist Publ Hopitaux De Paris |
Agents pour le traitement de tumeurs
|
JP6128529B2
(ja)
|
2011-07-19 |
2017-05-17 |
ウェイブ ライフ サイエンシズ リミテッドWave Life Sciences Ltd. |
官能化核酸の合成のための方法
|
EP3922722B1
(en)
|
2011-08-11 |
2023-06-28 |
Ionis Pharmaceuticals, Inc. |
Selective antisense compounds and uses thereof
|
US20140080896A1
(en)
|
2011-08-30 |
2014-03-20 |
The Regents Of The University Of California |
Identification of small molecules that facilitate therapeutic exon skipping
|
JP2015502365A
(ja)
|
2011-12-12 |
2015-01-22 |
オンコイミューニン,インコーポレイティド |
オリゴヌクレオチドのイン−ビボ送達
|
CN102675386B
(zh)
|
2011-12-24 |
2014-07-02 |
河南科技大学 |
一种龙胆苦苷分离提纯方法
|
WO2013134558A1
(en)
|
2012-03-07 |
2013-09-12 |
The Texas A & M University System |
Cancer treatment targeting non-coding rna overexpression
|
KR20130114435A
(ko)
|
2012-04-09 |
2013-10-17 |
삼성전자주식회사 |
다수의 전극을 갖는 생분자 검출 장치
|
WO2013179412A1
(ja)
|
2012-05-30 |
2013-12-05 |
北海道システム・サイエンス株式会社 |
高分散性液相支持体を用いたオリゴヌクレオチド合成法
|
CA2879066C
(en)
|
2012-07-13 |
2019-08-13 |
Shin Nippon Biomedical Laboratories, Ltd. |
Chiral nucleic acid adjuvant
|
JP6453212B2
(ja)
*
|
2012-07-13 |
2019-01-16 |
ウェイブ ライフ サイエンシズ リミテッドWave Life Sciences Ltd. |
キラル制御
|
DK2872485T3
(da)
|
2012-07-13 |
2021-03-08 |
Wave Life Sciences Ltd |
Asymmetrisk hjælpegruppe
|
EP2879718B1
(en)
|
2012-08-06 |
2023-06-07 |
Alnylam Pharmaceuticals, Inc. |
Processes for the preparation of carbohydrate conjugated rna agents
|
KR102237882B1
(ko)
|
2012-08-15 |
2021-04-07 |
아이오니스 파마수티컬즈, 인코포레이티드 |
변형된 캡핑 프로토콜을 이용하는 올리고머 화합물 제조 방법
|
DK2906256T3
(en)
|
2012-10-12 |
2018-11-19 |
Ionis Pharmaceuticals Inc |
SELECTIVE ANTISENSE COMPOUNDS AND APPLICATIONS THEREOF
|
AU2013346767B2
(en)
|
2012-11-15 |
2019-04-11 |
Roche Innovation Center Copenhagen A/S |
Oligonucleotide conjugates
|
DK2922955T3
(da)
|
2012-11-26 |
2019-05-13 |
Roche Innovation Ct Copenhagen As |
Sammensætninger og fremgangsmåder til modulering af FGFR3-ekspression
|
WO2014118272A1
(en)
|
2013-01-30 |
2014-08-07 |
Santaris Pharma A/S |
Antimir-122 oligonucleotide carbohydrate conjugates
|
RU2018108405A
(ru)
|
2013-01-30 |
2019-02-26 |
Ф. Хоффманн-Ля Рош Аг |
Конъюгаты углевода и lna-олигонуклеотида
|
ES2817050T3
(es)
|
2013-02-04 |
2021-04-06 |
Ionis Pharmaceuticals Inc |
Compuestos antisentido selectivos y usos de los mismos
|
NZ631552A
(en)
|
2013-05-01 |
2017-02-24 |
Ionis Pharmaceuticals Inc |
Compositions and methods for modulating hbv expression
|
CN105228999B
(zh)
|
2013-05-24 |
2021-03-02 |
味之素株式会社 |
吗啉代寡核苷酸的制备方法
|
BR112015029327A2
(pt)
|
2013-05-24 |
2017-09-19 |
Roche Innovation Ct Copenhagen As |
Moduladores de oligonucleotídeo de linfoma 11a/cll de célula b (bcl11a) e usos dos mesmos
|
PE20160158A1
(es)
|
2013-06-27 |
2016-03-18 |
Roche Innovation Ct Copenhagen As |
Oligomeros antisentido y conjugados con diana en pcsk9
|
TW202246503A
(zh)
|
2013-07-19 |
2022-12-01 |
美商百健Ma公司 |
用於調節τ蛋白表現之組合物
|
ES2750608T3
(es)
|
2013-07-25 |
2020-03-26 |
Exicure Inc |
Construcciones esféricas a base de ácido nucleico como agentes inmunoestimulantes para uso profiláctico y terapéutico
|
EA201690675A1
(ru)
|
2013-10-03 |
2016-08-31 |
Модерна Терапьютикс, Инк. |
Полинуклеотиды, кодирующие рецептор липопротеинов низкой плотности
|
US9988627B2
(en)
|
2013-10-04 |
2018-06-05 |
Novartis Ag |
Formats for organic compounds for use in RNA interference
|
CN105934524A
(zh)
|
2013-11-11 |
2016-09-07 |
桑格摩生物科学股份有限公司 |
用于治疗亨廷顿氏病的方法和组合物
|
CA2928349A1
(en)
|
2013-11-14 |
2015-05-21 |
Roche Innovation Center Copenhagen A/S |
Apob antisense conjugate compounds
|
US20150167017A1
(en)
|
2013-12-13 |
2015-06-18 |
Moderna Therapeutics, Inc. |
Alternative nucleic acid molecules and uses thereof
|
WO2015108046A1
(ja)
|
2014-01-15 |
2015-07-23 |
株式会社新日本科学 |
抗アレルギー作用を有するキラル核酸アジュバンド及び抗アレルギー剤
|
EP3095459A4
(en)
|
2014-01-15 |
2017-08-23 |
Shin Nippon Biomedical Laboratories, Ltd. |
Chiral nucleic acid adjuvant having antitumor effect and antitumor agent
|
WO2015108047A1
(ja)
|
2014-01-15 |
2015-07-23 |
株式会社新日本科学 |
免疫誘導活性を有するキラル核酸アジュバンド及び免疫誘導活性剤
|
SG10201912897UA
(en)
|
2014-01-16 |
2020-02-27 |
Wave Life Sciences Ltd |
Chiral design
|
WO2015168172A1
(en)
|
2014-04-28 |
2015-11-05 |
Isis Pharmaceuticals, Inc. |
Linkage modified oligomeric compounds
|
CA2946003A1
(en)
|
2014-05-01 |
2015-11-05 |
Ionis Pharmaceuticals, Inc. |
Compositions and methods for modulating angiopoietin-like 3 expression
|
RU2691102C2
(ru)
|
2014-05-08 |
2019-06-11 |
Сангамо Байосайенсиз, Инк. |
Способы и композиции для лечения болезни хантингтона
|
JP6663859B2
(ja)
|
2014-05-20 |
2020-03-13 |
ユニバーシティー オブ アイオワ リサーチ ファウンデーション |
ハンチントン病の治療化合物
|
US20160017327A1
(en)
|
2014-07-11 |
2016-01-21 |
The Johns Hopkins University |
Phosphorodiamidate morpholino oligomers (pmos) and their use in suppression of mutant huntingtin expression and attenuation of neurotoxicity
|
US20170204152A1
(en)
|
2014-07-16 |
2017-07-20 |
Moderna Therapeutics, Inc. |
Chimeric polynucleotides
|
EP2982758A1
(en)
|
2014-08-04 |
2016-02-10 |
Centre Hospitalier Universitaire Vaudois (CHUV) |
Genome editing for the treatment of huntington's disease
|
WO2016027168A2
(en)
|
2014-08-20 |
2016-02-25 |
Lifesplice Pharma Llc |
Splice modulating oligonucleotides and methods of use thereof
|
EP3186377A1
(en)
|
2014-08-20 |
2017-07-05 |
Alnylam Pharmaceuticals, Inc. |
Modified double-stranded rna agents
|
WO2016037191A1
(en)
|
2014-09-05 |
2016-03-10 |
Health Research, Inc. |
Use of huntingtin-derived plasmids and peptides for active immunization as a huntington's disease (hd) therapeutic
|
JP2017536119A
(ja)
|
2014-11-19 |
2017-12-07 |
ロシュ イノベーション センター コペンハーゲン エーエス |
キラルホスホロチオエート連結を含むlnaギャップマーオリゴヌクレオチド
|
WO2016096938A1
(en)
|
2014-12-16 |
2016-06-23 |
Roche Innovation Center Copenhagen A/S |
Chiral toxicity screening method
|
LT3237618T
(lt)
|
2014-12-24 |
2019-07-10 |
Uniqure Ip B.V. |
Rnri sukeltas hantingtino geno slopinimas
|
US9688707B2
(en)
|
2014-12-30 |
2017-06-27 |
Ionis Pharmaceuticals, Inc. |
Bicyclic morpholino compounds and oligomeric compounds prepared therefrom
|
CN107636159B
(zh)
|
2015-02-04 |
2022-06-14 |
百时美施贵宝公司 |
选择治疗性分子的方法
|
WO2016127002A1
(en)
|
2015-02-04 |
2016-08-11 |
Bristol-Myers Squibb Company |
Lna oligonucleotides with alternating flanks
|
BR112017017028A2
(pt)
|
2015-02-10 |
2018-04-10 |
Genzyme Corp |
rnai variante
|
WO2016130806A2
(en)
|
2015-02-13 |
2016-08-18 |
Alnylam Pharmaceuticals, Inc. |
Patatin-like phospholipase domain containing 3 (pnpla3) irna compositions and methods of use thereof
|
US10370659B2
(en)
|
2015-02-23 |
2019-08-06 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for increasing antisense activity
|
US20180036335A1
(en)
|
2015-03-03 |
2018-02-08 |
Ionis Pharmaceuticals, Inc. |
Compositions for modulating mecp2 expression
|
WO2016154096A1
(en)
|
2015-03-20 |
2016-09-29 |
Ionis Pharmaceuticals, Inc. |
Modulation of smggds expression
|
DK3277814T3
(da)
|
2015-04-03 |
2020-08-24 |
Univ Massachusetts |
Oligonukleotidforbindelser til målretning mod huntingtin-mrna
|
WO2016164896A2
(en)
|
2015-04-10 |
2016-10-13 |
Ionis Pharmaceuticals, Inc. |
Modulation of smn expression
|
WO2016167780A1
(en)
|
2015-04-16 |
2016-10-20 |
Ionis Pharmaceuticals, Inc. |
Compositions for modulating expression of c9orf72 antisense transcript
|
WO2016209862A1
(en)
|
2015-06-23 |
2016-12-29 |
Alnylam Pharmaceuticals, Inc. |
Glucokinase (gck) irna compositions and methods of use thereof
|
WO2017004261A1
(en)
|
2015-06-29 |
2017-01-05 |
Ionis Pharmaceuticals, Inc. |
Modified crispr rna and modified single crispr rna and uses thereof
|
KR102640776B1
(ko)
|
2015-07-10 |
2024-02-23 |
아이오니스 파마수티컬즈, 인코포레이티드 |
디아실글리세롤 아실전이효소 2(dgat2) 조절제
|
US10494632B2
(en)
|
2015-07-10 |
2019-12-03 |
Alnylam Pharmaceuticals, Inc. |
Insulin-like growth factor binding protein, acid labile subunit (IGFALS) compositions and methods of use thereof
|
CA2989970A1
(en)
|
2015-07-17 |
2017-01-26 |
Alnylam Pharmaceuticals, Inc. |
Multi-targeted single entity conjugates
|
MA43072A
(fr)
|
2015-07-22 |
2018-05-30 |
Wave Life Sciences Ltd |
Compositions d'oligonucléotides et procédés associés
|
WO2017019660A1
(en)
|
2015-07-27 |
2017-02-02 |
Alnylam Pharmaceuticals, Inc. |
Xanthine dehydrogenase (xdh) irna compositions and methods of use thereof
|
MA43335B1
(fr)
|
2015-07-31 |
2021-01-29 |
Alnylam Pharmaceuticals Inc |
Compositions d'arni de transthyrétine (ttr) et procédés pour les utiliser pour le traitement ou la prévention de maladies associées à ttr
|
DK3341479T3
(da)
|
2015-08-24 |
2020-02-24 |
Roche Innovation Ct Copenhagen As |
LNA-G-Proces
|
IL310959A
(en)
|
2015-08-25 |
2024-04-01 |
Alnylam Pharmaceuticals Inc |
Methods and preparations for treating a disorder related to the PCSK9 gene
|
PE20181131A1
(es)
|
2015-09-02 |
2018-07-17 |
Alnylam Pharmaceuticals Inc |
COMPOSICIONES DE ARNi PARA LIGANDO 1 DE MUERTE CELULAR PROGRAMADA 1 (PD-L1) Y METODOS DE USO DE LAS MISMAS
|
KR20180073584A
(ko)
|
2015-10-02 |
2018-07-02 |
로슈 이노베이션 센터 코펜하겐 에이/에스 |
올리고뉴클레오타이드 접합 방법
|
KR20180056766A
(ko)
|
2015-10-09 |
2018-05-29 |
웨이브 라이프 사이언시스 리미티드 |
뉴클레오티드 조성물 및 이의 방법
|
EP3394258B1
(en)
|
2015-10-22 |
2021-09-22 |
Roche Innovation Center Copenhagen A/S |
In vitro toxicity screening assay
|
WO2017068087A1
(en)
|
2015-10-22 |
2017-04-27 |
Roche Innovation Center Copenhagen A/S |
Oligonucleotide detection method
|
RS61529B9
(sr)
|
2015-11-12 |
2024-04-30 |
Hoffmann La Roche |
Oligonukleotidi za indukovanje ekspresije paternalnog ube3a
|
WO2017160741A1
(en)
|
2016-03-13 |
2017-09-21 |
Wave Life Sciences Ltd. |
Compositions and methods for phosphoramidite and oligonucleotide synthesis
|
JP6748219B2
(ja)
|
2016-03-14 |
2020-08-26 |
エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft |
Pd−l1発現低減用のオリゴヌクレオチド
|
US11267843B2
(en)
|
2016-03-18 |
2022-03-08 |
Roche Innovation Center Copenhagen A/S |
Stereodefining L-monomers
|
US11248019B2
(en)
|
2016-04-14 |
2022-02-15 |
Hoffmann-La Roche Inc. |
Trityl-mono-GalNAc compounds and their use
|
MA45290A
(fr)
|
2016-05-04 |
2019-03-13 |
Wave Life Sciences Ltd |
Procédés et compositions d'agents biologiquement actifs
|
MA45270A
(fr)
|
2016-05-04 |
2017-11-09 |
Wave Life Sciences Ltd |
Compositions d'oligonucléotides et procédés associés
|
EP3455232B1
(en)
|
2016-05-12 |
2020-05-06 |
Roche Innovation Center Copenhagen A/S |
Enhanced coupling of stereodefined oxazaphospholidine phosphoramidite monomers to nucleoside or oligonucleotide
|
EP3455354B1
(en)
|
2016-05-13 |
2023-07-12 |
Roche Diagnostics GmbH |
Protein-based sample collection matrices and devices
|
WO2017210647A1
(en)
|
2016-06-03 |
2017-12-07 |
Wave Life Sciences Ltd. |
Oligonucleotides, compositions and methods thereof
|
WO2018022473A1
(en)
|
2016-07-25 |
2018-02-01 |
Wave Life Sciences Ltd. |
Phasing
|
EP3544987A4
(en)
|
2016-11-23 |
2020-11-18 |
Wave Life Sciences Ltd. |
COMPOSITIONS AND SYNTHESIS OF PHOSPHORAMIDITES AND OLIGONUCLEOTIDES
|
JP2020522265A
(ja)
|
2017-06-02 |
2020-07-30 |
ウェイブ ライフ サイエンシズ リミテッドWave Life Sciences Ltd. |
オリゴヌクレオチド組成物及びその使用方法
|
EP3630199A4
(en)
|
2017-06-02 |
2021-11-10 |
Wave Life Sciences Ltd. |
OLIGONUCLEOTIDE COMPOSITIONS AND METHODS FOR THEIR USE
|
CA3065523A1
(en)
|
2017-06-02 |
2018-12-06 |
Wave Life Sciences Ltd. |
Oligonucleotide compositions and methods of use thereof
|
US11718638B2
(en)
|
2017-06-21 |
2023-08-08 |
Wave Life Sciences Ltd. |
Compounds, compositions and methods for synthesis
|
US11814407B2
(en)
|
2017-06-28 |
2023-11-14 |
Roche Innovation Center Copenhagen A/S |
Multiple coupling and oxidation method
|
AR112779A1
(es)
|
2017-08-08 |
2019-12-11 |
Wave Life Sciences Ltd |
Composiciones de nucleótidos y métodos relacionados
|
JP7472018B2
(ja)
|
2017-09-18 |
2024-04-22 |
ウェーブ ライフ サイエンシーズ リミテッド |
オリゴヌクレオチド調製のための技術
|
US11596646B2
(en)
|
2017-10-12 |
2023-03-07 |
Wave Life Sciences Ltd. |
Oligonucleotide compositions and methods thereof
|
AU2018392782B2
(en)
|
2017-12-21 |
2023-08-31 |
Alnylam Pharmaceuticals, Inc. |
Chirally-enriched double-stranded RNA agents
|
MX2020010687A
(es)
|
2018-04-12 |
2021-01-20 |
Wave Life Sciences Ltd |
Composiciones de oligonucleotidos y metodos de uso de las mismas.
|
EP3790596A4
(en)
|
2018-05-11 |
2022-04-06 |
Wave Life Sciences Ltd. |
OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE
|
CN113383078A
(zh)
|
2018-12-06 |
2021-09-10 |
波涛生命科学有限公司 |
寡核苷酸组合物及其方法
|
EP3917497A4
(en)
|
2019-02-01 |
2023-06-07 |
Wave Life Sciences Ltd. |
OLIGONUCLEOTIDE COMPOSITIONS AND RELATED METHODS
|
FR3093595B1
(fr)
|
2019-03-07 |
2022-03-11 |
Thales Sa |
Systeme de calibration depuis le sol d'une charge utile d'un satellite
|
SG11202110045PA
(en)
|
2019-03-20 |
2021-10-28 |
Wave Life Sciences Ltd |
Technologies useful for oligonucleotide preparation
|
JPWO2020196662A1
(ko)
|
2019-03-25 |
2020-10-01 |
|
|
MX2021012862A
(es)
|
2019-04-25 |
2022-03-04 |
Wave Life Sciences Ltd |
Composiciones de oligonucleotidos y metodos de uso de las mismas.
|
CA3137741A1
(en)
|
2019-04-25 |
2020-10-29 |
Wave Life Sciences Ltd. |
Oligonucleotide compositions and methods of use thereof
|
AU2020267775A1
(en)
|
2019-05-09 |
2021-12-02 |
Wave Life Sciences Ltd. |
Oligonucleotide compositions and methods of use thereof
|
KR20220070324A
(ko)
|
2019-10-06 |
2022-05-30 |
웨이브 라이프 사이언시스 리미티드 |
올리고뉴클레오티드 조성물 및 이의 이용 방법
|
MX2022004101A
(es)
|
2019-10-06 |
2022-04-26 |
Wave Life Sciences Ltd |
Composiciones de oligonucleotidos y metodos de uso de las mismas.
|
TW202146650A
(zh)
|
2020-03-01 |
2021-12-16 |
新加坡商波濤生命科學有限公司 |
寡核苷酸組成物及其方法
|
CA3176986A1
(en)
|
2020-05-22 |
2021-11-25 |
Wave Life Sciences Ltd. |
Oligonucleotide compositions and methods thereof
|